<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1860</journal-id><journal-id journal-id-type="pmc-domain">fcimb</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8712944</article-id><article-id pub-id-type="pmcid-ver">PMC8712944.1</article-id><article-id pub-id-type="pmcaid">8712944</article-id><article-id pub-id-type="pmcaiid">8712944</article-id><article-id pub-id-type="pmid">34970505</article-id><article-id pub-id-type="doi">10.3389/fcimb.2021.763687</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cellular and Infection Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tuli</surname><given-names initials="HS">Hardeep Singh</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/245399"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sak</surname><given-names initials="K">Katrin</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/740813"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names initials="P">Poonam</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1465304"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Iqubal</surname><given-names initials="A">Ashif</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/942136"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Upadhaya</surname><given-names initials="SK">Sushil K.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/724637"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kaur</surname><given-names initials="J">Jagjit</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1475110"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kaur</surname><given-names initials="G">Ginpreet</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/610520"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names initials="D">Diwakar</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1461419"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University)</institution>, <addr-line>Mullana</addr-line>, <country>India</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Non-Governmental Organization (NGO) Praeventio</institution>, <addr-line>Tartu</addr-line>, <country>Estonia</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>The Basic Research Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health</institution>, <addr-line>Frederick, MD</addr-line>, <country>United States</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Pharmacology, School of Pharmaceutical Education and Research (Formerly Faculty of Pharmacy), Jamia Hamdard (Deemed to be University)</institution>, <addr-line>Delhi</addr-line>, <country>India</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Graduate School of Biomedical Engineering, ARC Centre of Excellence in Nanoscale BioPhotonics (CNBP), Faculty of Engineering, The University of New South Wales</institution>, <addr-line>Sydney, NSW</addr-line>, <country>Australia</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, Shri Vile Parle Kelavani Mandal, Narsee Monjee Institute of Management Studies (SVKM&#8217;S NMIMS)</institution>, <addr-line>Mumbai</addr-line>, <country>India</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Rodolfo Garc&#237;a-Contreras, National Autonomous University of Mexico, Mexico</p></fn><fn fn-type="edited-by"><p>Reviewed by: Talha Bin Emran, Begum Gulchemonara Trust University, Bangladesh; Arif Ansori, Airlangga University, Indonesia; Ebru Saat&#231;i, Erciyes University, Turkey</p></fn><corresp id="fn001">*Correspondence: Hardeep Singh Tuli, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:hardeep.biotech@gmail.com">hardeep.biotech@gmail.com</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>12</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">375431</issue-id><elocation-id>763687</elocation-id><history><date date-type="received"><day>24</day><month>8</month><year>2021</year></date><date date-type="accepted"><day>19</day><month>10</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>12</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>29</day><month>12</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-07 09:25:22.453"><day>07</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2021 Tuli, Sak, Aggarwal, Iqubal, Upadhaya, Kaur, Kaur and Aggarwal</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Tuli, Sak, Aggarwal, Iqubal, Upadhaya, Kaur, Kaur and Aggarwal</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcimb-11-763687.pdf"/><abstract><p>Within almost the last 2 years, the world has been shaken by the coronavirus disease 2019 (COVID-19) pandemic, which has affected the lives of all people. With nearly 4.92 million deaths by October 19, 2021, and serious health damages in millions of people, COVID-19 has been the most serious global challenge after the Second World War. Besides lost lives and long-term health problems, devastating impact on economics, education, and culture will probably leave a lasting impression on the future. Therefore, the actual extent of losses will become obvious only after years. Moreover, despite the availability of different vaccines and vaccination programs, it is still impossible to forecast what the next steps of the virus are or how near we are to the end of the pandemic. In this article, the route of molecular evolution of the coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is thoroughly compiled, highlighting the changes that the virus has undergone during the last 2 years and discussing the approaches that the medical community has undertaken in the fight against virus-induced damages.</p></abstract><kwd-group><kwd>COVID pandemic</kwd><kwd>variants</kwd><kwd>molecular evolution</kwd><kwd>therapeutics</kwd><kwd>vaccination</kwd></kwd-group><counts><fig-count count="3"/><table-count count="3"/><equation-count count="0"/><ref-count count="137"/><page-count count="13"/><word-count count="6225"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>From the end of 2019, life has been greatly affected by the coronavirus disease 2019 (COVID-19) all over the world. Based on the data from Worldometers, this pandemic has afflicted more than 241.97 million human lives and has claimed nearly 4.92 million lives around the globe during the last 1.5 years (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.worldometers.info/coronavirus/">https://www.worldometers.info/coronavirus/</uri>; data from October 19, 2021). At that, the elderly people and those with underlying cardiovascular, respiratory, and metabolic disorders have been found to be especially vulnerable by severe course of the disease, causing bilateral pneumonia, acute respiratory distress syndrome (ARDS), failure of multiple organs (including, but not limited to, the brain, heart, liver, and kidneys), or even mortality (<xref rid="B1" ref-type="bibr">Abdullahi et&#160;al., 2020</xref>; <xref rid="B61" ref-type="bibr">Li et&#160;al., 2021</xref>). In addition to the direct health damages, devastating impact on education, culture, economics, and general public welfare proceeding from the strict restrictions in social contacts established for the disease prevention cannot be underestimated (<xref rid="B102" ref-type="bibr">Sood et&#160;al., 2020</xref>).</p><p>COVID-19 is caused by an infection with the single-stranded RNA virus with positive polarity, i.e., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that transmits mainly <italic toggle="yes">via</italic> respiratory droplets, aerosols, and fomites (<xref rid="B1" ref-type="bibr">Abdullahi et&#160;al., 2020</xref>; <xref rid="B54" ref-type="bibr">Kawabata et&#160;al., 2020</xref>; <xref rid="B61" ref-type="bibr">Li et&#160;al., 2021</xref>; <xref rid="B67" ref-type="bibr">Mallah et&#160;al., 2021</xref>). Coronaviruses consist of enveloped virus particles with 80&#8211;120 nm of diameter; they have typically spherical or pleomorphic structure with spike-like projections of glycoproteins on surface, giving them a crown-like appearance under electron microscopy (<xref rid="B112" ref-type="bibr">Tuli et&#160;al., 2021</xref>). The initial reservoir of SARS-CoV-2 is hypothesized to be bats transmitting the virus particles to human beings (<xref rid="B112" ref-type="bibr">Tuli et&#160;al., 2021</xref>). Within the time of the pandemic course, SARS-CoV-2 virus has been in a continuous molecular evolution, displaying genetic diversity and mutations with varied degrees of transmission and virulence (<xref rid="B1" ref-type="bibr">Abdullahi et&#160;al., 2020</xref>; <xref rid="B26" ref-type="bibr">Deimel et&#160;al., 2021</xref>). Such mutations can help virus particles to escape the immune system and/or replicate more efficiently once it has entered the host organism, making the virus more infectious and pathogenic (<xref rid="B2" ref-type="bibr">Adedokun et&#160;al., 2021</xref>; <xref rid="B42" ref-type="bibr">Hossain et&#160;al., 2021</xref>). The impact of viral changes on the COVID-19 pandemic has been apparent in the disease outbreaks occurring disproportionately in different parts of the world (<xref rid="B1" ref-type="bibr">Abdullahi et&#160;al., 2020</xref>; <xref rid="B33" ref-type="bibr">Fraser, 2020</xref>; <xref rid="B121" ref-type="bibr">Vudathaneni et&#160;al., 2021</xref>). Therefore, the virus variants are designated by the geographical regions where the mutations have emerged, including the UK (B.1.1.7), Brazilian (B.1.1.248), and South African (1.351) strains, among others (<xref rid="B42" ref-type="bibr">Hossain et&#160;al., 2021</xref>). Furthermore, as mutations in the virus genome can change also the susceptibility of the virus to both clinically used drugs and vaccines, concerns have been arisen about the efficacy of current preventive and therapeutic interventions for stopping the pandemic (<xref rid="B19" ref-type="bibr">Chiam et&#160;al., 2021</xref>; <xref rid="B42" ref-type="bibr">Hossain et&#160;al., 2021</xref>; <xref rid="B68" ref-type="bibr">Matta et&#160;al., 2021</xref>; <xref rid="B90" ref-type="bibr">Robinson et&#160;al., 2021</xref>).</p><p>In this state-of-the-art review article, molecular characteristics of the currently emerged variants of SARS-CoV-2 are under discussion, analyzing their infectivity, morbidity, and mortality potential, as well as susceptibility to the current intervention measures applied for achieving control over the pandemic.</p></sec><sec id="s2"><title>Molecular Evolution of Coronavirus Disease 2019 From Its Emergence to the Current State</title><p>Mutations originate as a result of viral replication during circulation. Despite being an RNA virus, coronaviruses undergo fewer mutations because of their strong proofread mechanism. Moreover, the fate of mutations is determined by the natural selection, meaning that those favored with respect to viral better survival will increase in frequency, and those that reduce viral fitness tend to be eliminated from the population of circulating viruses. However, mutations can also happen due to chance events. Therefore, the interplay of natural selection and chance events leads to virus evolution.</p><p>The SARS-CoV-2 virus has been mutated over time, resulting in different genetic variations in the population of circulating viral strains over the course of the COVID-19 pandemic. The evolution of SARS-CoV-2 suggests strong purifying selection and modest divergence; one of the most closely related strain of SARS-CoV-2 is &#8220;RaTG13&#8221; found in a bat sample from Yunnan Province, China, in 2013. RaTG13 (horseshoe bat, <italic toggle="yes">Rhinolophus affinis</italic>) shows 96% similarity to SARS-CoV-215. Though RaTG13 is closely related to SARS-CoV-2, there is a significant level of variation in sequence similarity across the genomes of these two viruses, ranging between 93.1% and 99.6% (<xref rid="B137" ref-type="bibr">Zhou et&#160;al., 2020</xref>). However, comparisons with other coronavirus strains suggest complex recombination events during its evolution. Various recombinations were detected across the genome majorly in ORF1a and in the region marking the N-terminus of the S protein (<xref rid="B62" ref-type="bibr">Li et&#160;al., 2003</xref>; <xref rid="B60" ref-type="bibr">Li, 2016</xref>; <xref rid="B40" ref-type="bibr">Hoffmann et&#160;al., 2020</xref>; <xref rid="B122" ref-type="bibr">Wan et&#160;al., 2020</xref>). S protein binds to angiotensin-converting enzyme 2 (ACE2) receptors and mediates viral entry into the human cells. One such mutation, D614G, arises as a result of single-nucleotide polymorphism (SNP) and results in amino acid change from an aspartate [D] to a glycine [G] at residue 614, increasing the efficiency of viral entry into the human cells (<xref rid="B48" ref-type="bibr">Isabel et&#160;al., 2020</xref>; <xref rid="B56" ref-type="bibr">Korber et&#160;al., 2020</xref>).</p><p>The D614G mutation in the spike glycoprotein of SARS-CoV-2 was significantly detected for the first time in early March 2020 and has spread globally across multiple geographic regions over the next month (<xref rid="B56" ref-type="bibr">Korber et&#160;al., 2020</xref>). However, various sequencing studies have already identified the D614G mutation in viruses in China in late January, which dispersed globally. Similarly, the population genetics analysis of more than 25,000 sequences from the United Kingdom also found that viruses with 614G are more transmissible and affect larger phylogenetic clusters (<xref rid="B119" ref-type="bibr">Volz et&#160;al., 2021</xref>). Even parallel studies in animal models also indicate that 614G viruses are more transmissible. As a result of more favored mutation, this strain has now become a dominant global strain (<xref rid="B43" ref-type="bibr">Hou et&#160;al., 2020</xref>; <xref rid="B81" ref-type="bibr">Plante et&#160;al., 2021</xref>).</p><p>Apart from its evolution in humans, there is evidence of cross-specific transmission in other animals like mink, which can even lead to emergence of potentially dangerous recombinant SARS-CoV-2 strains. Outbreaks of SARS-CoV-2 on mink farms in the Netherlands and Denmark that started in late spring and early summer 2020 demonstrated human-to-mink, mink-to-mink, and mink-to-human transmissions (<xref rid="B30" ref-type="bibr">European Centre for Disease Prevention and Control, 2020</xref>, <xref rid="B76" ref-type="bibr">Oude Munnink et&#160;al., 2021</xref>). In early November 2020, 214 cases of mink-associated human COVID-19 were reported. These cases where Y453F mutation in the receptor binding domain of spike might be responsible for increased binding affinity for ACE2 in mink. Eleven patients from the Danish outbreak had a cluster 5 variant having three additional mutations in spike (del69_70, I692V, and M1229I). An investigation of human serum samples in nine patients showed a significant reduction in neutralization activity against cluster 5 viruses (mean, 3.58-fold; range, 0&#8211;13.5). Therefore, continued evolution and adaptation of SARS-CoV-2 in an animal reservoir resulted in novel SARS-CoV-2 from mink to humans and other mammals.</p><p>Another lineage B.1.1.7 (also called 501Y.V1) was identified in southeastern England (<xref rid="B87" ref-type="bibr">Rambaut et&#160;al., 2021</xref>) and became one of the variants of the highest concern. This variant has already highly evolved, having 17 lineage-defining mutations even prior to its detection in early September. Seven of these mutations were in the spike proteins only that later formed the basis for the vaccine in the United Kingdom. This variant was found to be 56% more transmissible and was responsible for approximately 28% of cases of SARS-CoV-2 infection in England within 1 month (<xref rid="B24" ref-type="bibr">Davies et&#160;al., 2020</xref>). Unlike D614G, which could be because of chance events, B.1.1.7 (Alpha variant) strongly seems to have arisen as a result of natural selection. It came into existence after outcompeting already circulating widespread SARS-CoV variants.</p><p>Most of the mutations in B.1.1.7 lineage include mutations in the spike glycoprotein, N501Y in the receptor binding domain, deletion 69_70, and P681H in the furin cleavage site, which could probably influence ACE2 binding and viral replication. Specifically, the 501Y spike variants were predicted to have an increased affinity for human ACE2, and another variant, also with an N501Y mutation, was spreading fast in South Africa (Beta variant&#8212;B.a351, B.1.351.2, and B.1.353.3). Immunogenic effects of these mutations are currently not clear. Similarly, the Gamma variant (P.1) was emerged in the Amazon city of Manaus in December 2020 and has led to a surge in cases in Brazil (<xref rid="B10" ref-type="bibr">Buss et&#160;al., 2021</xref>).</p><p>Recently, the Delta variant (B.1.617.2, AY.1, and AY.2) having multiple mutations originated in India is of major concern (<xref rid="B15" ref-type="bibr">Centers for Disease Control and Prevention (CDC), 2021</xref>; <xref rid="B83" ref-type="bibr">Public Health England, 2021</xref>). This variant is the highest transmissible variant and hence favored by evolution. Therefore, different mutants originated in different geographical areas as a combinatorial result of selective advantage or chance mutation. Variants having mutations in spike to increase transmissibility could quickly outcompete and replace other circulating variants. Moreover, widespread infection among humans is now posing a huge threat to other mammals that usually interact with human populations and worsen the severity of disease by creating more dangerous recombinant SARS-CoV-2 strains. It would be important to consider the epidemiological, genetic, and functional studies of different variants and come up with a strong strategy to stop its transmission across the species.</p></sec><sec id="s3"><title>Geographically Emerged Strains and Their Structural Differences</title><p>Accumulation of mutations within the genome is the primary driving force in viral evolution within an endemic setting (<xref rid="B23" ref-type="bibr">Dan et&#160;al., 2020</xref>; <xref rid="B4" ref-type="bibr">Baden et&#160;al., 2021</xref>). This inherent feature often leads to altered virulence, infectivity and transmissibility, and antigenic shifts to escape host immunity, which might compromise the efficacy of vaccines and antiviral drugs (<xref rid="B113" ref-type="bibr">Upadhyay et&#160;al., 2021</xref>; <xref rid="B129" ref-type="bibr">Yadav et&#160;al., 2021a</xref>). The SARS-CoV-2 as RNA virus lacks mismatch repair mechanism and replication accompanied by a high mutation rate (<xref rid="B28" ref-type="bibr">Domingo and Holland, 1997</xref>). Therefore, the mutations of the coronavirus are commonsensical and predictable, which leads to several rapidly spreading variants (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). At present, emergence of fast-spreading three SARS-CoV-2 variants (B.1.1.7, B.1.351, and B.1.1.28.1) due to rapid mutations in ACE2 became dominant strains all around the world, causing concern on prevention and treatment of COVID-19 (<xref rid="B57" ref-type="bibr">Krammer, 2020</xref>; <xref rid="B11" ref-type="bibr">Callaway, 2021</xref>; <xref rid="B136" ref-type="bibr">Zhou and Wang, 2021</xref>). The morphological and physiological assessments of the P.1 or B.1.1.28.1 variant of SARS-CoV-2 from Brazil reflected less resistance to antibodies produced from natural infection or vaccination compared with other parallel variants B.1.351 from South Africa, and B.1.1.7 from the United Kingdom (<xref rid="B31" ref-type="bibr">Faria et&#160;al., 2021</xref>). It is noteworthy that P.1, B.1.1.7, and B.1.351 have accrued multiple mutations in the NTD (N-terminal domain) and can be neutralized by a monoclonal antibody, mAb 222 (<xref rid="B16" ref-type="bibr">Cerutti et&#160;al., 2021</xref>; <xref rid="B27" ref-type="bibr">Dejnirattisai et&#160;al., 2021</xref>). In addition, these mutated residues also have the potential to modulate vaccine-induced antibody responses (<xref rid="B106" ref-type="bibr">Supasa et&#160;al., 2021</xref>; <xref rid="B135" ref-type="bibr">Zhou et&#160;al., 2021</xref>). The three central variants by analyzing 160 sequences claimed that B-type viruses (with substitution, NS8_L84S) were common in East Asia, whereas A-type (ancestral lineage) and C-type (NS3_G251V variant) viruses were prevalent in Europe and North America (<xref rid="B32" ref-type="bibr">Forster et&#160;al., 2020</xref>). Along with other co-evolving mutations, NSP12_P323L and S_D614G probably provide variants with an evolutionary advantage over their ancestral types, allowing them to survive and circulate in this densely populated region (<xref rid="B5" ref-type="bibr">Becerra-Flores and Cardozo, 2020</xref>; <xref rid="B49" ref-type="bibr">Islam et&#160;al., 2021</xref>). Thus, the recent emergence of a number of variants of concern (VOCs) has led to design of new vaccines that will be able to protect against the emerging viral variants.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Different variants of SARS-CoV-2 according to the WHO.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">S. no.</th><th valign="top" align="center" rowspan="1" colspan="1">Variant name</th><th valign="top" align="center" rowspan="1" colspan="1">1st detected by</th><th valign="top" align="center" rowspan="1" colspan="1">Month, year of detection</th><th valign="top" align="center" rowspan="1" colspan="1">Key mutations in spike protein</th><th valign="top" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">614G</td><td valign="top" align="left" rowspan="1" colspan="1">Bavaria, Germany</td><td valign="top" align="left" rowspan="1" colspan="1">January, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">D614G</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B9" ref-type="bibr">Br&#252;ssow, 2021</xref>; <xref rid="B81" ref-type="bibr">Plante et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>2</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">20C-US</td><td valign="top" align="left" rowspan="1" colspan="1">United States</td><td valign="top" align="left" rowspan="1" colspan="1">May, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">Q677; Q173</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B78" ref-type="bibr">Pater et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>3</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1.427/B.1.429 (also known as Epsilon variant)</td><td valign="top" align="left" rowspan="1" colspan="1">United States</td><td valign="top" align="left" rowspan="1" colspan="1">June, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">L452R; W152C; S13I; D614G</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B110" ref-type="bibr">Tomkins-Tinch et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>4</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1.1.7 (also known as 20I/501Y.V1 or VOC202012/01 or Alpha variant)</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom</td><td valign="top" align="left" rowspan="1" colspan="1">September, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">H69/V70; Y144; N501Y; A570D; P681H</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B59" ref-type="bibr">Leung et&#160;al., 2021</xref>; <xref rid="B99" ref-type="bibr">Sarkar et&#160;al., 2021a</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>5</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">CAL., 20C</td><td valign="top" align="left" rowspan="1" colspan="1">Southern California</td><td valign="top" align="left" rowspan="1" colspan="1">October, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">ORF1a: I4205V; ORF1b: D1183Y; S13I; W152C; L452R</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B134" ref-type="bibr">Zhang et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1.526 (also known as Iota variant)</td><td valign="top" align="left" rowspan="1" colspan="1">United States</td><td valign="top" align="left" rowspan="1" colspan="1">November, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">L5F; T95I; D253G; D614G; A701V; E484K or S477N</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B125" ref-type="bibr">West et&#160;al., 2021b</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>7</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1.525 (also known as Eta variant)</td><td valign="top" align="left" rowspan="1" colspan="1">United Kingdom,<break/>Nigeria</td><td valign="top" align="left" rowspan="1" colspan="1">December, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">H69-V70; Y144; Q52R;<break/>E484K; Q677H; D614G; F888L</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B31" ref-type="bibr">Faria et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>8</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1.351 (also known as 20H/501Y.V2 or Beta variant)</td><td valign="top" align="left" rowspan="1" colspan="1">South Africa</td><td valign="top" align="left" rowspan="1" colspan="1">December, 2020</td><td valign="top" align="left" rowspan="1" colspan="1">L242/A243/L244; K417N; E484K; N501Y</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B109" ref-type="bibr">Tegally et&#160;al., 2021</xref>; <xref rid="B126" ref-type="bibr">WHO, 2021a</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>9</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1 descendant with 9 mutations</td><td valign="top" align="left" rowspan="1" colspan="1">France</td><td valign="top" align="left" rowspan="1" colspan="1">January, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">G142; D66H; Y144V; D215G; V483A; D614G; H655Y; G669S; Q949R; N1187D</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B124" ref-type="bibr">West et&#160;al., 2021a</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>10</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1.1.28.1 (also known as P.1 or Gamma variant)</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil/Japan</td><td valign="top" align="left" rowspan="1" colspan="1">January, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">K417T, E484K; N501Y</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B95" ref-type="bibr">Sabino et&#160;al., 2021</xref>; <xref rid="B20" ref-type="bibr">Chudik et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>11</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1.1.28.3 (also known as P.3 or Theta variant)</td><td valign="top" align="left" rowspan="1" colspan="1">Philippines</td><td valign="top" align="left" rowspan="1" colspan="1">February, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">E484K; N501Y; P681H</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B38" ref-type="bibr">Haseltine, 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>12</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1.1.28.2 (also known as P.2 or Zeta variant)</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil</td><td valign="top" align="left" rowspan="1" colspan="1">April, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">L18F; T20N; P26S; F157L; E484K; D614G; S929I; V1176F</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B31" ref-type="bibr">Faria et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>13</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1.617.2 (also known as Delta variant)</td><td valign="top" align="left" rowspan="1" colspan="1">London, United Kingdom, India</td><td valign="top" align="left" rowspan="1" colspan="1">March&#8211;May, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">T19R, (V70F*), T95I, G142D, E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), L452R, T478K, D614G, P681R, D950N</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B97" ref-type="bibr">Salvatore et&#160;al., 2021</xref>; <xref rid="B128" ref-type="bibr">Williams et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>14</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">B.1.617.1/B.1.617.3 (also known as Kappa variant)</td><td valign="top" align="left" rowspan="1" colspan="1">Maharashtra India</td><td valign="top" align="left" rowspan="1" colspan="1">February, 2021</td><td valign="top" align="left" rowspan="1" colspan="1">G142D; E154K; L452R; E484Q; D614G; P681R; Q1071H</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B18" ref-type="bibr">Cherian et&#160;al., 2021</xref>; <xref rid="B127" ref-type="bibr">WHO, 2021b</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.</p></fn></table-wrap-foot></table-wrap><p>The comprehensive analysis of whole-genome sequences of 837 Indian SARS-CoV-2 strains revealed the occurrence of 33 different mutations, 18 of which were unique to India (<xref rid="B107" ref-type="bibr">Tang et&#160;al., 2020</xref>; <xref rid="B98" ref-type="bibr">Sarkar et&#160;al., 2021b</xref>). The second SARS-CoV-2 epidemic wave in India began around March 2021, and just weeks after, it became the dominant lineage by superseding the previous lineages (<xref rid="B53" ref-type="bibr">Kar et&#160;al., 2021</xref>; <xref rid="B97" ref-type="bibr">Salvatore et&#160;al., 2021</xref>). Almost all new cases of COVID-19 are the Delta variant (B.1.617.2) with augmented cases, but the rate of growth is slower than that of the Alpha variant (<xref rid="B73" ref-type="bibr">O&#8217;Dowd, 2021</xref>). The data showed the even at the higher risk of hospitalization for patients with the Delta variant compared with the Alpha variant (B.1.1.7), two doses of vaccine gave a high degree (90%) of protection (<xref rid="B101" ref-type="bibr">Shrotri et&#160;al., 2021</xref>; <xref rid="B105" ref-type="bibr">Stowe et&#160;al., 2021</xref>; <xref rid="B128" ref-type="bibr">Williams et&#160;al., 2021</xref>). The identification and spread of various dreading variants including B.1.1.7, B.1.351, and P.1 in India led to global VOCs (<xref rid="B3" ref-type="bibr">Alai et&#160;al., 2021</xref>). The Kappa and Delta variant lineages of SARS-CoV-2 were first detected in December 2020 in India (<xref rid="B18" ref-type="bibr">Cherian et&#160;al., 2021</xref>). Rapidly between January and February 2021, the Delta (B.1.617.2) variant became dominant in Maharashtra and was marked as a VOC in early May by the <xref rid="B127" ref-type="bibr">WHO (2021b)</xref>. Therefore, it is imperative that currently known variants of COVID-19 and new variants should be carefully considered in the design of an effective vaccine.</p><sec id="s3_1"><title>Variability in Infectivity, Morbidity, and Mortality of Different Strains</title><p>The case fatality rate (CFR) in COVID-19 seems to be elevated than that of in seasonal influenza, whereas both diseases principally have an effect on older adults above 65 years of age with infirmity (<xref rid="B23" ref-type="bibr">Dan et&#160;al., 2020</xref>; <xref rid="B130" ref-type="bibr">Yadav et&#160;al., 2021b</xref>). The augmented fatality rate of COVID-19 could be because of variations in underlying comorbidities of patients, pathogenicity of the causative agent SARS-CoV-2, immunity of population, and responses of host to the infection (<xref rid="B50" ref-type="bibr">Jha et&#160;al., 2020</xref>; <xref rid="B115" ref-type="bibr">Upadhyay et&#160;al., 2020a</xref>; <xref rid="B114" ref-type="bibr">Upadhyay et&#160;al., 2020b</xref>). It has been reported that the COVID-19 patients were more frequently obese and suffered from diabetes, hypertension, and dyslipidemia than influenza patients; on the contrary, the influenza patients often had cardiac failure, chronic respiratory disease, cirrhosis, and anemia (<xref rid="B80" ref-type="bibr">Piroth et&#160;al., 2021</xref>). Patients admitted to care centers with new variant of SARS-CoV-2 more frequently experienced acute respiratory failure, pulmonary embolism, septic shock, or hemorrhagic stroke, but less frequently developed myocardial infarction or atrial fibrillation (<xref rid="B23" ref-type="bibr">Dan et&#160;al., 2020</xref>). In-hospital mortality was comparatively multifold higher in patients with COVID-19 than conventional influenza patients (16.9% <italic toggle="yes">vs.</italic> 5.8%, respectively), with a relative risk of death of 2.9 (<xref rid="B125" ref-type="bibr">West et&#160;al., 2021b</xref>). Quantitatively, there was less pediatric patients (&lt;18 years) for COVID-19 than influenza among the patients admitted in the hospital, but a bigger proportion of patients younger than 5 years required intensive care unit (ICU) support to COVID-19 than influenza (<xref rid="B80" ref-type="bibr">Piroth et&#160;al., 2021</xref>). As per the report, in-hospital mortality of adolescents (11&#8211;17 years) was manyfold higher for COVID-19 than for influenza as well. Thus, the effect of the SARS-CoV-2 variant is tremendous for all sex and age groups of the human population but was&#160;supposed to be the most common challenging health risk factor to immunocompromised septuagenarians and octogenarians (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Risk of infectivity and morbidity among COVID-19 patients: <bold>(A)</bold> sex based, <bold>(B)</bold> age based, and <bold>(C)</bold> comorbidities. COVID-19, coronavirus disease 2019.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-11-763687-g001.jpg"/></fig></sec></sec><sec id="s4"><title>Susceptibility of Coronavirus Disease 2019 to Clinically Used Drugs</title><p>Currently, the strategy to treat the COVID-19 infection comprises social distancing and vaccination. However, with the sharp rise in the cases and variable symptoms, various pharmacotherapies were explored for enhancing viral clearance and other symptomatic relief (<xref rid="B86" ref-type="bibr">Rahman and Idid, 2021</xref>). Until now, no specific drug for the treatment and management of COVID-19 has been developed. Hence, the focus has been shifted towards drug repurposing, which is time saving, is an accepted approach, and has an unmet need of time (<xref rid="B103" ref-type="bibr">Stasi et&#160;al., 2020</xref>). At present, many of the existing drugs have been repurposed and tested in preclinical and clinical trials (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>). However, with the advancement and better understanding of pathophysiology and clinical presentation among patients, it was noticed that the clinical efficacy of these drugs depends on timing of use, disease stage, and dose regimen (<xref rid="B45" ref-type="bibr">Iqubal et&#160;al., 2021a</xref>). Antiviral drugs are important when used during the early stage, as they inhibit viral entry and replication (<xref rid="B93" ref-type="bibr">&#350;im&#351;ek Yavuz and &#220;nal, 2020</xref>). Among antiviral drugs, remdesivir is one of the extensively used drugs. Initially, the <italic toggle="yes">in vitro</italic> study has shown antiviral potential against COVID-19. Later on, the US Food and Drug Administration (FDA) approved this drug to shorten the recovery time in adults and children (below the age of 12) (<xref rid="B132" ref-type="bibr">Young et&#160;al., 2021</xref>). However, the outcome of the WHO SOLIDARITY trial that involved 11,330 patients across 40 countries showed a non-significant effect on reducing mortality, duration of hospitalization, and need of a mechanical ventilator (<xref rid="B41" ref-type="bibr">Horby et&#160;al., 2020</xref>). Lopinavir/ritonavir is a combination therapy for HIV, and it was proposed to be an effective therapy for COVID-19 (<xref rid="B13" ref-type="bibr">Cao et&#160;al., 2020</xref>). Ivermectin is an approved antiparasitic drug (<xref rid="B12" ref-type="bibr">Caly et&#160;al., 2020</xref>). Initially, the <italic toggle="yes">in vitro</italic> study showed that ivermectin significantly inhibited the replication; but based on the outcome of a double-blinded randomized trial, no clinical efficacy of lopinavir/ritonavir and ivermectin among COVID-19-infected patients were found (<xref rid="B65" ref-type="bibr">L&#243;pez-Medina et&#160;al., 2021</xref>). These drugs are not in use now. Hydroxychloroquine and chloroquine were also claimed to be promising therapeutic modality against COVID-19 infection, but the outcome of the randomized trial showed a non-significant effect against symptomatic relief among COVID-19 patients (<xref rid="B72" ref-type="bibr">Mitj&#224; et&#160;al., 2021</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Details of various repurposed drugs in COVID-19 infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="2" align="left" rowspan="1">Class of drugs</th><th valign="top" align="center" rowspan="1" colspan="1">Drugs</th><th valign="top" align="center" rowspan="1" colspan="1">Mechanism of action</th><th valign="top" align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" rowspan="6" colspan="2" align="left">
<bold>Antivirals</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Remdesivir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of RNA-dependent RNA polymerase and, hence, compete for viral ATP, which results in inhibition of viral replication</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B132" ref-type="bibr">Young et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lopinavir/ritonavir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of 3-chymotrypsin-like protease (3CL<sup>pro</sup>) and inhibit viral replication</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B13" ref-type="bibr">Cao et&#160;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ivermectin</td><td valign="top" align="left" rowspan="1" colspan="1">Blocker importin &#945;/&#946; receptor and, hence, inhibit the transmission of viral protein into the nucleus of host cell</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B12" ref-type="bibr">Caly et&#160;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ribavirin</td><td valign="top" align="left" rowspan="1" colspan="1">Potent inhibitor of viral RNA synthesis</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B46" ref-type="bibr">Iqubal et&#160;al., 2021b</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Favipiravir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of RNA-dependent RNA polymerase and, hence, compete for viral ATP, which results in inhibition of viral replication</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B46" ref-type="bibr">Iqubal et&#160;al., 2021b</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Umifenovir</td><td valign="top" align="left" rowspan="1" colspan="1">Affects the S protein activity and, hence, inhibit its fusion with the host cell</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B46" ref-type="bibr">Iqubal et&#160;al., 2021b</xref>
</td></tr><tr><td valign="top" rowspan="8" colspan="2" align="left">
<bold>Immunomodulators</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Corticosteroids</bold>
<list list-type="bullet"><list-item><p>Dexamethasone</p></list-item><list-item><p>Hydrocortisone</p></list-item><list-item><p>Methylprednisolone</p></list-item></list>
</td><td valign="top" align="left" rowspan="1" colspan="1">Effectively mitigate the pro-inflammatory signaling pathways, stimulate the anti-inflammatory pathways, inhibit COX as well as NF-kB-mediated hyperinflammation, and, hence, reduce the cytokine storm</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B37" ref-type="bibr">Hamilton et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>IFN &#946;-1a</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Potentiate the interferon and assist in viral clearance</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B25" ref-type="bibr">Davoudi-Monfared et&#160;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>IL-6R-antagonists</bold>
<list list-type="bullet"><list-item><p>Tocilizumab</p></list-item><list-item><p>Sarilumab</p></list-item></list>
</td><td valign="top" rowspan="2" align="left" colspan="1">Inhibit IL-6-mediated hyperinflammation and cytokine storm</td><td valign="top" rowspan="2" align="left" colspan="1">
<xref rid="B71" ref-type="bibr">Michot et&#160;al., 2020</xref>; <xref rid="B35" ref-type="bibr">Gordon et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>IL-1R antagonists</bold>
<break/>Anakinra</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>TNF-&#945; inhibitors</bold>
<break/>Adalimumab</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibit TNF-&#945;-mediated hyperinflammation and control cytokine storm</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B45" ref-type="bibr">Iqubal et&#160;al., 2021a</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Bruton&#8217;s tyrosine kinase inhibitors</bold>
<list list-type="bullet"><list-item><p>Ibrutinib</p></list-item><list-item><p>Rilzabrutinib</p></list-item><list-item><p>Acalabrutinib</p></list-item></list>
</td><td valign="top" align="left" rowspan="1" colspan="1">Potent inhibitor of TLR-4 activation and, therefore, mitigate the cytokine storm and inflammatory pathway</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B91" ref-type="bibr">Roschewski et&#160;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>JAK inhibitors</bold>
<list list-type="bullet"><list-item><p>Baricitinib</p></list-item><list-item><p>Fedratinib</p></list-item></list>
</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibit JAK and activate STAT pathway, leading to inhibition of cytokine production and maturation.<break/>Additionally, these drugs inhibit the viral endocytosis <italic toggle="yes">via</italic> interacting with ACE2</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B104" ref-type="bibr">Stebbing et&#160;al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Calcineurin inhibitors</bold>
<break/>*&#8195;Cyclosporine<break/>*&#8195;Tacrolimus</td><td valign="top" align="left" rowspan="1" colspan="1">Reduced the production of T-lymphocytes <italic toggle="yes">via</italic> tumbling the expression of IL-2 receptor and production of IL-2.<break/>Inhibit the viral replication</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Cavagna et&#160;al., 2020</xref>
</td></tr><tr><td valign="top" colspan="2" align="left" rowspan="1">
<bold>Complement inhibitors</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Eculizumab</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibit the production of inflammatory C5a and C5b-9</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B58" ref-type="bibr">Laurence et&#160;al., 2020</xref>
</td></tr><tr><td valign="top" rowspan="2" colspan="2" align="left">
<bold>Kinin&#8211;kallikrein pathway inhibitors</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Lanadelumab</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of kallikrein and hence offers relief from ARDS</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B63" ref-type="bibr">Lipcsey et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Icatibant</td><td valign="top" align="left" rowspan="1" colspan="1">Antagonist of bradykinin receptor type 2 and thus, inhibit hyperinflammation</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" colspan="2" align="left" rowspan="1">
<bold>Serine protease inhibitors</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>C1 esterase inhibitor</bold>
<list list-type="bullet"><list-item><p>Camostat mesylate</p></list-item><list-item><p>Nafamostat mesylate</p></list-item></list>
</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibit the coagulation and ARDS <italic toggle="yes">via</italic> interacting with FXIIa and kallikrein</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B116" ref-type="bibr">Urwyler et&#160;al., 2020</xref>
</td></tr><tr><td valign="top" rowspan="2" colspan="2" align="left">
<bold>Antimalarials</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Hydroxychloroquine</td><td valign="top" rowspan="1" align="left" colspan="1">Inhibit the viral entry, replication, cytokine production and coagulation</td><td valign="top" rowspan="1" align="left" colspan="1">
<xref rid="B72" ref-type="bibr">Mitj&#224; et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chloroquine</td></tr><tr><td valign="top" rowspan="4" colspan="2" align="left">
<bold>Blood-derived products</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Convalescent plasma</td><td valign="top" rowspan="1" align="left" colspan="1">Maintain and stimulate the physiological defense against viral infection</td><td valign="top" rowspan="1" align="left" colspan="1">
<xref rid="B47" ref-type="bibr">Iqubal et&#160;al., 2021c</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hyperimmune immunoglobulin</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bamlanivimab</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-spike neutralizing IgG1 monoclonal antibody that interferes with the function of viral spike proteins</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B36" ref-type="bibr">Gottlieb et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>REGN-COV2</bold>
<list list-type="bullet"><list-item><p>Casirivimab</p></list-item><list-item><p>Bamlanivimab</p></list-item><list-item><p>Imdevimab</p></list-item><list-item><p>Etesevimab</p></list-item><list-item><p>Sotrovimab</p></list-item></list>
</td><td valign="top" align="left" rowspan="1" colspan="1">Cocktail of two anti-spike neutralizing antibodies that that interfere the function of viral spike proteins</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B108" ref-type="bibr">Tardif et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" rowspan="5" align="left" colspan="1">
<bold>Miscellaneous</bold>
</td><td valign="top" colspan="2" align="left" rowspan="1">&#8195;&#8195; Colchicine</td><td valign="top" align="left" rowspan="1" colspan="1">Reduce hyperinflammation</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B108" ref-type="bibr">Tardif et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" colspan="2" align="left" rowspan="1">&#8195;&#8195; Vitamin D</td><td valign="top" align="left" rowspan="1" colspan="1">Maintain the immune function (innate and adaptive immune system).<break/>Reduce oxidative stress, inflammation and scavenge free radicals.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B34" ref-type="bibr">Giannini et&#160;al., 2021</xref>
</td></tr><tr><td valign="top" colspan="2" align="left" rowspan="1">Azithromycin</td><td valign="top" align="left" rowspan="1" colspan="1">Assist in viral clearance and inhibit viral replication.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B74" ref-type="bibr">Oldenburg and Doan, 2020</xref>
</td></tr><tr><td valign="top" colspan="2" align="left" rowspan="1">Sirolimus</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibit T-cell differentiation <italic toggle="yes">via</italic> inhibiting mTOR pathway and, hence, reduces cytokine storm and ARDS.</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B75" ref-type="bibr">Omarjee et&#160;al., 2020</xref>
</td></tr><tr><td valign="top" colspan="2" align="left" rowspan="1">Bevacizumab</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of IL-6 and hence reduces the severity of cytokine storm and ARDS</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B77" ref-type="bibr">Pang et&#160;al., 2021</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>COVID-19, coronavirus disease 2019; ARDS, acute respiratory distress syndrome.</p></fn></table-wrap-foot></table-wrap><p>Use of corticosteroids and immunotherapy is preferred during cytokine storms or at the hyperinflammatory stage, and inappropriate use of these drugs often results in fetal immunogenic reactions (<xref rid="B29" ref-type="bibr">Esmaeilzadeh and Elahi, 2021</xref>; <xref rid="B84" ref-type="bibr">Rabaan et&#160;al., 2021</xref>).</p><p>Based on various clinical findings, corticosteroids were reported to be effective against cytokine storm and hyperinflated lungs (<xref rid="B39" ref-type="bibr">Hassan et&#160;al., 2020</xref>; <xref rid="B100" ref-type="bibr">Shang et&#160;al., 2020</xref>). The outcome of the landmark RECOVERY trial that involved confirmed patients of COVID-19 showed that the use of dexamethasone resulted in reduced mortality and need of mechanical ventilators or oxygen supply (<xref rid="B37" ref-type="bibr">Hamilton et&#160;al., 2021</xref>). Based on this trial, dexamethasone was approved among critically ill patients, either alone or in combination with remdesivir (<xref rid="B118" ref-type="bibr">Vetter et&#160;al., 2020</xref>; <xref rid="B69" ref-type="bibr">Mehta et&#160;al., 2021</xref>). Interferon-&#946;-1a, a cytokine, exhibits an immunogenic response against viral infection (<xref rid="B133" ref-type="bibr">Yuen et&#160;al., 2020</xref>). Previously, interferon-&#946;-1a showed clinical ineffectiveness against ARDS but exhibited a positive response among the patients of COVID-19 (<xref rid="B8" ref-type="bibr">Bosi et&#160;al., 2020</xref>; <xref rid="B51" ref-type="bibr">Kali et&#160;al., 2021</xref>; <xref rid="B111" ref-type="bibr">Tortajada et&#160;al., 2021</xref>). Interferon-&#946;-1a, when used during the early stage of infection, reduced the duration of hospitalization and mortality rate (<xref rid="B25" ref-type="bibr">Davoudi-Monfared et&#160;al., 2020</xref>). However, recent findings have shown that interferon-&#946;-1a is ineffective against Alpha (B.1.1.7), Beta (B.1.351), Gamma (P1), and Delta (B.1.617.2) strains (<xref rid="B25" ref-type="bibr">Davoudi-Monfared et&#160;al., 2020</xref>). Currently, interferon-&#946;-1a is not recommended for treating COVID-19 patients (<xref rid="B25" ref-type="bibr">Davoudi-Monfared et&#160;al., 2020</xref>). Similar to interferon-&#946;-1a, anakinra (interleukin-1 antagonist) was found to be effective in reducing mortality during the initial investigation, but recent findings have shown its ineffectiveness against B.1.1.7; B.1.351, and P.1 variants and, hence, are not recommended to treat COVID-19-infected patients (<xref rid="B44" ref-type="bibr">Huet et&#160;al., 2020</xref>). Tocilizumab (IL-6 receptor antibody) and sarilumab as well as siltuximab (IL-receptor antagonist) are effective during hyperinflammatory state; and hence, they were explored for possible protective effects in COVID-19 infection (<xref rid="B71" ref-type="bibr">Michot et&#160;al., 2020</xref>). Some clinical trials, such as REMAP and RECOVERY, showed the benefit of using tocilizumab, sarilumab, and siltuximab, which reduced mortality and showed a better safety profile among infected patients (<xref rid="B71" ref-type="bibr">Michot et&#160;al., 2020</xref>; <xref rid="B35" ref-type="bibr">Gordon et&#160;al., 2021</xref>). Janus kinase (JAK) inhibitors (baricitinib, ruxolitinib, and tofacitinib) are well-known drugs approved for rheumatoid arthritis and other inflammatory conditions (<xref rid="B104" ref-type="bibr">Stebbing et&#160;al., 2020</xref>). Baricitinib is considered as one of the potential drug candidates against COVID-19 infection (<xref rid="B94" ref-type="bibr">Saber-Ayad et&#160;al., 2021</xref>). This drug acts by inhibiting viral endocytosis in the <italic toggle="yes">in vitro</italic> study and inhibits the altered hyperinflammatory signaling pathway (<xref rid="B89" ref-type="bibr">Richardson et&#160;al., 2020</xref>). In ACTT-2 trial, when baricitinib was used in combination with remdesivir, it showed superior clinical efficacy in reducing ARDS and mortality rate as compared with baricitinib alone (<xref rid="B52" ref-type="bibr">Kalil et&#160;al., 2021</xref>). Currently, the combination of baricitinib and remdesivir is approved by the US FDA for the treatment of COVID-19 infection (<xref rid="B52" ref-type="bibr">Kalil et&#160;al., 2021</xref>). Apart from JAK inhibitor, Bruton&#8217;s tyrosine kinase inhibitors such as rilzabrutinib, ibrutinib, and acalabrutinib are currently approved by the US FDA for the treatment of hematological malignancy (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>) (<xref rid="B88" ref-type="bibr">Rezaei et&#160;al., 2020</xref>; <xref rid="B6" ref-type="bibr">Benner and Carson, 2021</xref>; <xref rid="B85" ref-type="bibr">Rada et&#160;al., 2021</xref>). These drugs act as an inhibitor macrophage activation, which is a rate-limiting step during cytokine storm (<xref rid="B91" ref-type="bibr">Roschewski et&#160;al., 2020</xref>). Therefore, these drugs are hypothesized to be a future therapeutic candidate against COVID-19 infection (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>). More recently, anti-SARS-CoV-2-neutralizing antibodies such as casirivimab, bamlanivimab, imdevimab, etesevimab, and sotrovimab were approved by the US FDA for the treatment of non-hospitalized patients with a confirmed report of COVID-19 infection (<xref rid="B66" ref-type="bibr">Mahase, 2021</xref>; <xref rid="B117" ref-type="bibr">Verderese et&#160;al., 2021</xref>; <xref rid="B123" ref-type="bibr">Weinreich et&#160;al., 2021</xref>).</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Schematic representation of mechanisms of action of COVID-19 therapeutics by inhibiting endocytosis, ACE2 receptor, and viral replication. COVID-19, coronavirus disease 2019; ACE2, angiotensin-converting enzyme 2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-11-763687-g002.jpg"/></fig></sec><sec id="s5"><title>Differences in Efficacy of Vaccines on Preventing Infection With Coronavirus Disease 2019 Strains and Controlling Necessity for Hospitalization</title><p>COVID-19 vaccines play a critical role in helping the countries to overcome the challenging pandemic that they are currently grappling with. It is believed that the severity of the pandemic will gradually reduce as the herd immunity is achieved. However, there may be factors that make it difficult to achieve herd immunity such as receiving only one dose of the vaccine for which two doses are required, denial to get vaccinated, and shortage of the vaccines. Therefore, it is very important to mass vaccinate the population completely if we want to win the battle over the pandemic (<xref rid="B17" ref-type="bibr">Chen and Lu, 2021</xref>). A public&#8211;private partnership was initiated by the US government to speed up development, approval, and distribution of the COVID-19 vaccines (<xref rid="B21" ref-type="bibr">Corey et&#160;al., 2020</xref>). Most of the COVID-19 vaccines have spike glycoprotein of SARS-CoV-2 as their basis. The commonly used vaccines are as follows: BNT162b2 (Pfizer-BioNTech) (<xref rid="B82" ref-type="bibr">Polack et&#160;al., 2020</xref>), ChAdOx1 nCOV19 (Oxford-AstraZeneca) (<xref rid="B120" ref-type="bibr">Voysey et&#160;al., 2021</xref>), NVX-CoV2373 (Novavax) (<xref rid="B55" ref-type="bibr">Keech et&#160;al., 2020</xref>), mRNA-1273 (NIAID-Moderna) (<xref rid="B4" ref-type="bibr">Baden et&#160;al., 2021</xref>), and Ad26COV2S (Janssen) (<xref rid="B96" ref-type="bibr">Sadoff et&#160;al., 2021</xref>). There are several preprints, peer-reviewed publications, press releases, policy documents, and public regulatory documents that demonstrate the efficacy and safety of these vaccines (<xref rid="B55" ref-type="bibr">Keech et&#160;al., 2020</xref>; <xref rid="B82" ref-type="bibr">Polack et&#160;al., 2020</xref>; <xref rid="B4" ref-type="bibr">Baden et&#160;al., 2021</xref>; <xref rid="B120" ref-type="bibr">Voysey et&#160;al., 2021</xref>). A study was conducted to study the efficacy of BNT162b2 vaccine (<xref rid="B22" ref-type="bibr">Dagan et&#160;al., 2021</xref>) during the mass vaccination in Israel. The participants were followed up 7 days after the second dose, and it was found that the vaccine has an efficacy of 94% for symptomatic COVID-19 participants, 92% for people with severe COVID-19, 92% for people with documented infection, and 87% for the people admitted in the hospitals. It was also concluded that the effectiveness of the vaccine was lower in people who suffer from various coexisting medical conditions like hypertension and obesity than in healthy individuals. Similar results were found in England for adults aged 70 years and over, indicating that the BNT162b2 vaccine showed 85%&#8211;90% efficacy after the second dose (<xref rid="B64" ref-type="bibr">Lopez Bernal et&#160;al., 2021</xref>). The risk of being admitted to hospitals was reduced by 44% in the vaccinated people, whereas the risk of death was reduced by 51%. They also studied the efficacy of ChAdOx1-S vaccine and found out that a single dose was 60%&#8211;75% effective in people with symptomatic COVID-19 and that the risks of hospital admission were reduced up to 80% in the vaccinated people. Various vaccines are being manufactured and distributed across the globe (<xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>) to control the pandemic. <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3</bold>
</xref> summarizes the mechanisms of action of investigated anti-COVID-19 vaccines. These vaccines have helped in reducing the number of COVID-19 cases; however, the efficacy may vary in different studies. In the earlier phases of vaccination, it was found that the people receiving the vaccination were more prone to COVID-19 infection, which encouraged people to defer the vaccines. However, it was found that the infection occurred when people travelled to infected region or encountered COVID-19-positive patients, and the risk of infection was higher in the first 3 days of vaccination. This period was before the incubation of vaccine occurred, which rules out the odds of vaccination.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table&#160;3</label><caption><p>Various vaccines available for COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Vaccine</th><th valign="top" align="center" rowspan="1" colspan="1">Manufacturer</th><th valign="top" align="center" rowspan="1" colspan="1">Origin of vaccine</th><th valign="top" align="center" rowspan="1" colspan="1">Dose(s) required</th><th valign="top" align="center" rowspan="1" colspan="1">Efficacy against COVID-19</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">BNT162b2 or Comirnaty</td><td valign="top" align="left" rowspan="1" colspan="1">Pfizer-BioNTech; Fosun Pharma</td><td valign="top" align="left" rowspan="1" colspan="1">m-RNA-based vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses, 21 days apart</td><td valign="top" align="left" rowspan="1" colspan="1">94% (<xref rid="B22" ref-type="bibr">Dagan et&#160;al., 2021</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ChAdOx1-S or AstraZeneca or Covishield (India)</td><td valign="top" align="left" rowspan="1" colspan="1">Oxford-AstraZeneca</td><td valign="top" align="left" rowspan="1" colspan="1">Adenovirus vector expressed in chimpanzee</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses, 28 days apart</td><td valign="top" align="left" rowspan="1" colspan="1">60%&#8211;75% (<xref rid="B64" ref-type="bibr">Lopez Bernal et&#160;al., 2021</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NVX-CoV2373</td><td valign="top" align="left" rowspan="1" colspan="1">Novavax</td><td valign="top" align="left" rowspan="1" colspan="1">Spike protein expressed in baculovirus</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses, 21 days apart</td><td valign="top" align="left" rowspan="1" colspan="1">95.6% (<xref rid="B66" ref-type="bibr">Mahase, 2021</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gam-Covid-Vac or Sputnik V</td><td valign="top" align="left" rowspan="1" colspan="1">Gamaleya Research Institute, Acellena Contract Drug Research and Development</td><td valign="top" align="left" rowspan="1" colspan="1">Spike protein expressed in adenovirus Ad5 and Ad26 vectors</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses, 21 days apart</td><td valign="top" align="left" rowspan="1" colspan="1">92% (<xref rid="B92" ref-type="bibr">Roxby, 2020</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Moderna COVID-19 vaccine or mRNA-1273</td><td valign="top" align="left" rowspan="1" colspan="1">Moderna, U.S. Biomedical Advanced Research and Development Authority (<xref rid="B22" ref-type="bibr">Dagan et&#160;al., 2021</xref>), National Institute of Allergy and Infectious Diseases (NIAID)</td><td valign="top" align="left" rowspan="1" colspan="1">m-RNA vaccine expressing adenovirus type 26 (dose 1) and adenovirus type 5 (dose 2)</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses, 28 days apart</td><td valign="top" align="left" rowspan="1" colspan="1">94.5% (<xref rid="B120" ref-type="bibr">Voysey et&#160;al., 2021</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Covaxin</td><td valign="top" align="left" rowspan="1" colspan="1">Bharat Biotech, Indian Council of Medical Research (ICMR)</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated virus vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses, 28 days apart</td><td valign="top" align="left" rowspan="1" colspan="1">81% (<xref rid="B7" ref-type="bibr">Biotech, 2021</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BBIBP-CorV</td><td valign="top" align="left" rowspan="1" colspan="1">Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated virus vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses, 21 or 28 days apart</td><td valign="top" align="left" rowspan="1" colspan="1">79% (<xref rid="B131" ref-type="bibr">Yan et&#160;al., 2021</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">JNJ-78436735 or Ad26.COV2.S or Janssen COVID-19 vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Janssen Biotech Inc.&#8212;Janssen Pharmaceutical Company of Johnson &amp; Johnson</td><td valign="top" align="left" rowspan="1" colspan="1">Spike protein expressed in adenovirus Ad26 vector</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses, 56 days apart</td><td valign="top" align="left" rowspan="1" colspan="1">76.7%&#8211;85.4% for severe COVID-19 patients (<xref rid="B131" ref-type="bibr">Yan et&#160;al., 2021</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CoronaVac</td><td valign="top" align="left" rowspan="1" colspan="1">Sinovac</td><td valign="top" align="left" rowspan="1" colspan="1">Whole inactivated virus vaccines with alum as an adjuvant</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses, 14&#8211;28 days apart</td><td valign="top" align="left" rowspan="1" colspan="1">50%&#8211;91% (<xref rid="B131" ref-type="bibr">Yan et&#160;al., 2021</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EpiVacCorona</td><td valign="top" align="left" rowspan="1" colspan="1">Federal Budgetary Research Institution State Research Center of Virology and Biotechnology</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">2 doses, 21&#8211;28 days apart</td><td valign="top" align="left" rowspan="1" colspan="1">100% (Phase I and Phase II trials) <xref rid="B70" ref-type="bibr">Merah et&#160;al. (2021)</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ad5-nCoV or Convidicea</td><td valign="top" align="left" rowspan="1" colspan="1">CanSino Biologics</td><td valign="top" align="left" rowspan="1" colspan="1">Spike protein expressed in adenovirus Ad5 vector</td><td valign="top" align="left" rowspan="1" colspan="1">1 dose</td><td valign="top" align="left" rowspan="1" colspan="1">90.98% (interim analysis) (<xref rid="B79" ref-type="bibr">Peshimam and Farooq, 2021</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ZF2001</td><td valign="top" align="left" rowspan="1" colspan="1">Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">3 doses within 90 days</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Name not yet announced</td><td valign="top" align="left" rowspan="1" colspan="1">Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">72.5% (interim analysis) (<xref rid="B131" ref-type="bibr">Yan et&#160;al., 2021</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>COVID-19, coronavirus disease 2019.</p></fn><fn><p>NA, Not Applicable.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>The vaccines (viral vector and nucleic acid vaccines) are administered through intramuscular or intradermal routes, and antigen expression is initiated in the cells. The B cells and T cells generate the humoral immune response and cell-mediated immune response, respectively. The cell-mediated immune response produces the cytokines that kill the infected cells, and humoral cells produce antibodies that prevent the COVID-19 infection. COVID-19, coronavirus disease 2019.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-11-763687-g003.jpg"/></fig><p>Most of these vaccines were manufactured against the original strain of SARS-CoV-2, and since then, the virus has mutated several times. It is crucial to develop a wide-spectrum vaccine that is effective against the various strains of SARS-CoV-2. In addition, for controlling the COVID-19, it is very important that the global population may be vaccinated completely. It is the duty of the officials to build trust among the public and encourage them to get vaccinated. The eradication of this disease is only possible when the herd immunity is achieved by vaccinating the people globally.</p></sec><sec id="s6"><title>Possibilities to Facilitate Overcoming Coronavirus Disease 2019 Pandemic</title><p>Considering the rapid molecular evolution of SARS-CoV-2 virus from its emergence to the present moment, continuous surveillance is required to identify novel mutations with potential ability to bypass current measures for controlling COVID-19. In the near future, readiness to react to such changes in virus genome is probably unavoidable. Rapid ongoing vaccination with continuously improved and updated vaccines or even vaccine cocktails is obviously the only human-controlled proactive way to impede the pandemic. Taking into consideration the fact that increased transmission can enhance the probability of further mutations (<xref rid="B68" ref-type="bibr">Matta et&#160;al., 2021</xref>), quick vaccination of the most active (younger) age groups seems to be the best strategy for preventing the appearance of novel hazardous mutations. On the other hand, the possibility of emergence of a mutant virus variant with high prevalence (high transmissibility) but low virulence cannot be avoided, overriding the spread of the current high-lethality strains and changing the fatal disease course to be much milder, thereby ensuring the &#8220;friendly&#8221; coexistence of virus and humankind in the future. Which of these scenarios will come true is just the question of time; still, it is clear that the lessons that this pandemic has taught to humankind are absolutely unique and tremendous.</p></sec><sec sec-type="conclusions" id="s7"><title>Conclusions</title><p>Within already nearly the last 2 years, humankind of the 21st century has undergone unexpectedly complicated challenges related to the COVID-19 pandemic, from total social isolation to different mass-vaccination campaigns. However, despite biotechnological prosperity and ultrafast preparation of vaccines, we still cannot look to the future with peace of mind, as the virus is circulating among populations even after the use of current vaccines, and we have no means to forecast the virulence and lethality of potentially developing novel strains. Therefore, our location within this pandemic can be decided only retrospectively, and it remains to be hoped that after 5 years we will estimate today&#8217;s position as the end of the pandemic.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author Contributions</title><p>HT performed the literature survey and data extraction. KS contributed in the introduction and conclusion. PA contributed in the molecular evolution. AI contributed in the therapeutic section. SU contributed in the geographic distribution section. JK contributed in the vaccination section. GK and DA contributed in final proofing and editing. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#8217;s Note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdullahi</surname><given-names>I. N.</given-names></name><name name-style="western"><surname>Emeribe</surname><given-names>A. U.</given-names></name><name name-style="western"><surname>Ajayi</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Oderinde</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Amadu</surname><given-names>D. O.</given-names></name><name name-style="western"><surname>Osuji</surname><given-names>A. I.</given-names></name></person-group> (<year>2020</year>). <article-title>Implications of SARS-CoV-2 Genetic Diversity and Mutations on Pathogenicity of the COVID-19 and Biomedical Interventions</article-title>. <source>J. Taibah Univ. Med. Sci.</source><volume>15</volume> (<issue>4</issue>), <fpage>258</fpage>&#8211;<lpage>264</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jtumed.2020.06.005</pub-id><pub-id pub-id-type="pmid">32837505</pub-id><pub-id pub-id-type="pmcid">PMC7351386</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adedokun</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Olarinmoye</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Olayemi</surname><given-names>L. O.</given-names></name><name name-style="western"><surname>Shehu</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Mustapha</surname><given-names>J. O.</given-names></name><name name-style="western"><surname>Kamorudeen</surname><given-names>R. T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Addressing the Global Surge of COVID-19 Cases: Insights From Diagnostics, Improved Treatment Strategies, Vaccine Development and Application</article-title>. <source>J. Clin. Transl. Res.</source><volume>7</volume> (<issue>2</issue>), <fpage>127</fpage>&#8211;<lpage>139</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.18053/jctres.07.202102.00</pub-id><pub-id pub-id-type="pmid">34104816</pub-id><pub-id pub-id-type="pmcid">PMC8177856</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gujar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gairola</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Pan-India Novel Coronavirus SARS-CoV-2 Genomics and Global Diversity Analysis in Spike Protein</article-title>. <source>Heliyon</source><volume>7</volume> (<issue>3</issue>):<elocation-id>e06564</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.heliyon.2021.e06564</pub-id><pub-id pub-id-type="pmid">33758785</pub-id><pub-id pub-id-type="pmcid">PMC7972664</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title>. <source>N. Engl. J. Med.</source><volume>384</volume> (<issue>5</issue>), <fpage>403</fpage>&#8211;<lpage>416</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becerra-Flores</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cardozo</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Viral Spike G614 Mutation Exhibits Higher Case Fatality Rate</article-title>. <source>Int. J. Clin. Pract.</source><volume>74</volume> (<issue>8</issue>), <fpage>e13525</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/ijcp.13525</pub-id><pub-id pub-id-type="pmid">32374903</pub-id><pub-id pub-id-type="pmcid">PMC7267315</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>W. E.</given-names></name></person-group> (<year>2021</year>). <article-title>Observations on the Use of Bruton's Tyrosine Kinase Inhibitors in SAR-CoV-2 and Cancer</article-title>. <source>J. Hematol. Oncol.</source><volume>14</volume> (<issue>1</issue>), <fpage>15</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13045-020-00999-8</pub-id><pub-id pub-id-type="pmid">33441177</pub-id><pub-id pub-id-type="pmcid">PMC7805262</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Biotech</surname><given-names>B</given-names></name></person-group>. (<year>2021</year>). <source>Bharat Biotech Announces Phase 3 Results of COVAXIN: Indias First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%</source> (<publisher-loc>Hyderabad, TS</publisher-loc>), <fpage>3</fpage>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bharatbiotech.com/images/press/covaxin-phase3-efficacy-results.pdf">https://www.bharatbiotech.com/images/press/covaxin-phase3-efficacy-results.pdf</uri>.</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bosi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rovere Querini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Calori</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ruggeri</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Interferon &#946;-1a (IFN&#946;-1a) in COVID-19 Patients (INTERCOP): Study Protocol for a Randomized Controlled Trial</article-title>. <source>Trials</source><volume>21</volume> (<issue>1</issue>), <fpage>939</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13063-020-04864-4</pub-id><pub-id pub-id-type="pmid">33225960</pub-id><pub-id pub-id-type="pmcid">PMC7681191</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Br&#252;ssow</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19: Emergence and Mutational Diversification of SARS-CoV-2</article-title>. <source>Microb. Biotechnol.</source><volume>14</volume> (<issue>3</issue>), <fpage>756</fpage>&#8211;<lpage>768</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/1751-7915.13800</pub-id><pub-id pub-id-type="pmid">33750009</pub-id><pub-id pub-id-type="pmcid">PMC8085963</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buss</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Prete</surname><given-names>C. A.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Abrahim</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mendrone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salomon</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Almeida-Neto</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Three-Quarters Attack Rate of SARS-CoV-2 in the Brazilian Amazon During a Largely Unmitigated Epidemic</article-title>. <source>Science (New York N.Y.)</source><volume>371</volume> (<issue>6526</issue>), <fpage>288</fpage>&#8211;<lpage>292</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abe9728</pub-id><pub-id pub-id-type="pmcid">PMC7857406</pub-id><pub-id pub-id-type="pmid">33293339</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>Fast-Spreading COVID Variant can Elude Immune Responses</article-title>. <source>Nature</source><volume>589</volume>, <fpage>500</fpage>&#8211;<lpage>501</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/d41586-021-00121-z</pub-id><pub-id pub-id-type="pmid">33479534</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caly</surname><given-names>L.</given-names></name><name name-style="western"><surname>Druce</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Catton</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Jans</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Wagstaff</surname><given-names>K. M.</given-names></name></person-group> (<year>2020</year>). <article-title>The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 <italic toggle="yes">In Vitro</italic>
</article-title>. <source>Antiviral Res.</source><volume>178</volume>, <elocation-id>104787</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id><pub-id pub-id-type="pmid">32251768</pub-id><pub-id pub-id-type="pmcid">PMC7129059</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A Trial of Lopinavir-Ritonavir in Adults Hospitalized With Severe Covid-19</article-title>. <source>N. Engl. J. Med.</source><volume>382</volume> (<issue>19</issue>), <fpage>1787</fpage>&#8211;<lpage>1799</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id><pub-id pub-id-type="pmid">32187464</pub-id><pub-id pub-id-type="pmcid">PMC7121492</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavagna</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seminari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zanframundo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gregorini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Matteo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rampino</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results From a Multidisciplinary Cohort of Patients in Northern Italy</article-title>. <source>Microorganisms</source><volume>8</volume> (<issue>7</issue>), <elocation-id>977</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/microorganisms8070977</pub-id><pub-id pub-id-type="pmcid">PMC7409165</pub-id><pub-id pub-id-type="pmid">32629788</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>CDC</collab></person-group> (<year>2021</year>). <source>COVID-19: SARS-CoV-2 Variant Classifications and Definitions. Department of Health and Human Services</source> (<publisher-loc>USA</publisher-loc>: <publisher-name>CDC Atlanta, GA</publisher-name>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html">https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html</uri>.</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerutti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gorman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rapp</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite</article-title>. <source>Cell Host Microbe</source><volume>29</volume> (<issue>5</issue>), <fpage>819</fpage>&#8211;<lpage>833.e7</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.01.10.426120</pub-id><pub-id pub-id-type="pmid">33789084</pub-id><pub-id pub-id-type="pmcid">PMC7953435</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>New Challenges to Fighting COVID-19: Virus Variants, Potential Vaccines, and Development of Antivirals</article-title>. <source>Biosci. Trends</source><volume>15</volume> (<issue>2</issue>), <fpage>126</fpage>&#8211;<lpage>128</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.5582/bst.2021.01092</pub-id><pub-id pub-id-type="pmid">33746183</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Potdar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jadhav</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Das</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Convergent Evolution of SARS-CoV-2 Spike Mutations, L452R, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India</article-title>. <source>Microorganisms</source><volume>9</volume> (<issue>7</issue>), <fpage>1542</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.04.22.440932</pub-id><pub-id pub-id-type="pmid">34361977</pub-id><pub-id pub-id-type="pmcid">PMC8307577</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiam</surname><given-names>T.</given-names></name><name name-style="western"><surname>Subedi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Best</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>F. B.</given-names></name><name name-style="western"><surname>Dobler</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Hospital Length of Stay Among COVID-19-Positive Patients</article-title>. <source>J. Clin. Transl. Res.</source><volume>7</volume> (<issue>3</issue>), <fpage>377</fpage>&#8211;<lpage>385</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.chom.2021.03.005</pub-id><pub-id pub-id-type="pmid">34239994</pub-id><pub-id pub-id-type="pmcid">PMC8259605</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chudik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pesaran</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Rebucci</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <source>COVID-19 Time-Varying Reproduction Numbers Worldwide: An Empirical Analysis of Mandatory and Voluntary Social Distancing</source>. <publisher-name>Cambridge, MA</publisher-name>: (<publisher-name>NBER Work. Pap. Ser</publisher-name>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nber.org/system/files/working_papers/w28629/w28629.pdf">https://www.nber.org/system/files/working_papers/w28629/w28629.pdf</uri>.</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>F. S.</given-names></name></person-group> (<year>2020</year>). <article-title>A Strategic Approach to COVID-19 Vaccine R&amp;D</article-title>. <source>Science (New York N.Y.)</source><volume>368</volume> (<issue>6494</issue>), <fpage>948</fpage>&#8211;<lpage>950</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abc5312</pub-id><pub-id pub-id-type="pmid">32393526</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dagan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kepten</surname><given-names>E.</given-names></name><name name-style="western"><surname>Miron</surname><given-names>O.</given-names></name><name name-style="western"><surname>Perchik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting</article-title>. <source>N. Engl. J. Med.</source><volume>384</volume> (<issue>15</issue>), <fpage>1412</fpage>&#8211;<lpage>1423</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2101765</pub-id><pub-id pub-id-type="pmid">33626250</pub-id><pub-id pub-id-type="pmcid">PMC7944975</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pant</surname><given-names>M.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>S. K.</given-names></name></person-group> (<year>2020</year>). <article-title>The Case Fatality Rate in Covid-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic</article-title>. <source>Curr. Pharmacol. Rep.</source><fpage>1</fpage>&#8211;<lpage>10</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s40495-020-00239-0</pub-id><pub-id pub-id-type="pmcid">PMC7490208</pub-id><pub-id pub-id-type="pmid">32953401</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>C. I.</given-names></name><name name-style="western"><surname>Kucharski</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Munday</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>C. A. B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Estimated Transmissibility and Severity of Novel SARS-CoV-2 Variant of Concern 202012/01 in England</article-title>. <source>Science</source><volume>372</volume> (<issue>6538</issue>), <fpage>eabg3055</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abg3055</pub-id><pub-id pub-id-type="pmcid">PMC8128288</pub-id><pub-id pub-id-type="pmid">33658326</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davoudi-Monfared</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rahmani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hajiabdolbaghi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abbasian</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A Randomized Clinical Trial of the Efficacy and Safety of Interferon &#946;-1a in Treatment of Severe COVID-19</article-title>. <source>Antimicrob. Agents Chemother.</source><volume>64</volume> (<issue>9</issue>), <fpage>e01061</fpage>&#8211;<lpage>e01020</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/AAC.01061-20</pub-id><pub-id pub-id-type="pmid">32661006</pub-id><pub-id pub-id-type="pmcid">PMC7449227</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deimel</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ranasinghe</surname><given-names>C.</given-names></name></person-group> (<year>2021</year>). <article-title>Interleukin-13 as a Target to Alleviate Severe Coronavirus Disease 2019 and Restore Lung Homeostasis</article-title>. <source>J. Clin. Transl. Res.</source><volume>7</volume> (<issue>1</issue>), <fpage>116</fpage>&#8211;<lpage>120</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.18053/jctres.07.202101.0</pub-id><pub-id pub-id-type="pmid">34027204</pub-id><pub-id pub-id-type="pmcid">PMC8132187</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dejnirattisai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Supasa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Ginn</surname><given-names>H. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Antibody Evasion by the P.1 Strain of SARS-CoV-2</article-title>. <source>Cell</source><volume>184</volume> (<issue>11</issue>), <fpage>2939</fpage>&#8211;<lpage>2954:e9</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2021.03.055</pub-id><pub-id pub-id-type="pmid">33852911</pub-id><pub-id pub-id-type="pmcid">PMC8008340</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domingo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>J. J.</given-names></name></person-group> (<year>1997</year>). <article-title>RNA Virus Mutations and Fitness for Survival</article-title>. <source>Annu. Rev. Microbiol.</source><volume>51</volume>, <fpage>151</fpage>&#8211;<lpage>178</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev.micro.51.1.151</pub-id><pub-id pub-id-type="pmid">9343347</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esmaeilzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elahi</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Immunobiology and Immunotherapy of COVID-19: A Clinically Updated Overview</article-title>. <source>J. Cell Physiol.</source><volume>236</volume> (<issue>4</issue>), <fpage>2519</fpage>&#8211;<lpage>2543</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jcp.30076</pub-id><pub-id pub-id-type="pmid">33022076</pub-id><pub-id pub-id-type="pmcid">PMC7675260</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>European Centre for Disease Prevention and Control</collab></person-group> (<year>2020</year>). <source>Detection of New SARS-CoV-2 Variants Related to Mink</source> (<publisher-loc>Stockholm</publisher-loc>: <publisher-name>ECDC</publisher-name>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ecdc.europa.eu/sites/default/files/documents/RRASARS-CoV-2-in-mink-12-nov-2020.pdf">https://www.ecdc.europa.eu/sites/default/files/documents/RRASARS-CoV-2-in-mink-12-nov-2020.pdf</uri>.</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Faria</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Claro</surname><given-names>I. M.</given-names></name><name name-style="western"><surname>Candido</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moyses</surname></name><name name-style="western"><surname>Franco</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>P. S.</given-names></name><etal/></person-group> (<year>2021</year>) <source>Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in Manaus: Preliminary Findings. SARS-CoV-2 Coronavirus / Ncov-2019 Genomic Epidemiology</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://virological.org/t/genomiccharacterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminaryfindings/586">https://virological.org/t/genomiccharacterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminaryfindings/586</uri>.</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forster</surname><given-names>P.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>L.</given-names></name><name name-style="western"><surname>Renfrew</surname><given-names>C.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Phylogenetic Network Analysis of SARS-CoV-2 Genomes</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>117</volume> (<issue>17</issue>), <fpage>9241</fpage>&#8211;<lpage>9243</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.2004999117</pub-id><pub-id pub-id-type="pmid">32269081</pub-id><pub-id pub-id-type="pmcid">PMC7196762</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fraser</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 Strains Remote Regions of Peru</article-title>. <source>Lancet</source><volume>395</volume> (<issue>10238</issue>), <fpage>1684</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31236-8</pub-id><pub-id pub-id-type="pmid">32473669</pub-id><pub-id pub-id-type="pmcid">PMC7255738</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giannini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Passeri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tripepi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sella</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fusaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arcidiacono</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study</article-title>. <source>Nutrients</source><volume>13</volume> (<issue>1</issue>), <elocation-id>219</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/nu13010219</pub-id><pub-id pub-id-type="pmid">33466642</pub-id><pub-id pub-id-type="pmcid">PMC7828675</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Mouncey</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Al-Beidh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rowan</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Nichol</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Arabi</surname><given-names>Y. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Interleukin-6 Receptor Antagonists in Critically Ill Patients With Covid-19</article-title>. <source>N. Engl. J. Med.</source><volume>384</volume> (<issue>16</issue>), <fpage>1491</fpage>&#8211;<lpage>1502</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2100433</pub-id><pub-id pub-id-type="pmid">33631065</pub-id><pub-id pub-id-type="pmcid">PMC7953461</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Nirula</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boscia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heller</surname><given-names>B.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial</article-title>. <source>JAMA</source><volume>325</volume> (<issue>7</issue>), <fpage>632</fpage>&#8211;<lpage>644</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.2021.0202</pub-id><pub-id pub-id-type="pmid">33475701</pub-id><pub-id pub-id-type="pmcid">PMC7821080</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>F. W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Lilford</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hemming</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Is Convalescent Plasma Futile in COVID-19? A Bayesian Re-Analysis of the RECOVERY Randomized Controlled Trial</article-title>. <source>Int. J. Infect. Dis.</source><volume>109</volume>, <fpage>114</fpage>&#8211;<lpage>117</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ijid.2021.06.034</pub-id><pub-id pub-id-type="pmid">34157385</pub-id><pub-id pub-id-type="pmcid">PMC8214317</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Haseltine</surname><given-names>W. A.</given-names></name></person-group> (<year>2021</year>). <source>A New Variant in the Philippines</source>. <publisher-loc>Philippines</publisher-loc>: <publisher-name>Forbes</publisher-name>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.forbes.com/sites/williamhaseltine/2021/03/18/third-generation-covid-19-variant-described-in-the-philippines/?sh=617be2b973ca">https://www.forbes.com/sites/williamhaseltine/2021/03/18/third-generation-covid-19-variant-described-in-the-philippines/?sh=617be2b973ca</uri>.</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Sridharan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Elkady</surname><given-names>A.</given-names></name><name name-style="western"><surname>ElSeirafi</surname><given-names>M. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Dexamethasone in Severe COVID-19 Infection: A Case Series</article-title>. <source>Respir. Med. Case Rep.</source><volume>31</volume>, <elocation-id>101205</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.rmcr.2020.101205</pub-id><pub-id pub-id-type="pmid">32874905</pub-id><pub-id pub-id-type="pmcid">PMC7452843</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Erichsen</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>. <source>Cell</source><volume>181</volume> (<issue>2</issue>), <fpage>271</fpage>&#8211;<lpage>280.e8</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horby</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mafham</surname><given-names>M.</given-names></name><name name-style="western"><surname>Linsell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Staplin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>J. R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effect of Hydroxychloroquine in Hospitalized Patients With Covid-19</article-title>. <source>N. Engl. J. Med.</source><volume>383</volume> (<issue>21</issue>), <fpage>2030</fpage>&#8211;<lpage>2040</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2022926</pub-id><pub-id pub-id-type="pmid">33031652</pub-id><pub-id pub-id-type="pmcid">PMC7556338</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hossain</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Hassanzadeganroudsari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V.</given-names></name></person-group> (<year>2021</year>). <article-title>The Emergence of New Strains of SARS-CoV-2. What Does it Mean for COVID-19 Vaccines</article-title>? <source>Expert Rev. Vaccines</source><volume>1</volume>, <elocation-id>4</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14760584.2021.1915140</pub-id><pub-id pub-id-type="pmcid">PMC8074646</pub-id><pub-id pub-id-type="pmid">33896316</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Chiba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Halfmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ehre</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dinnon</surname><given-names>K. H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 D614G Variant Exhibits Efficient Replication Ex Vivo and Transmission <italic toggle="yes">In Vivo</italic>
</article-title>. <source>Science (New York N.Y.)</source><volume>370</volume> (<issue>6523</issue>), <fpage>1464</fpage>&#8211;<lpage>1468</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abe8499</pub-id><pub-id pub-id-type="pmcid">PMC7775736</pub-id><pub-id pub-id-type="pmid">33184236</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huet</surname><given-names>T.</given-names></name><name name-style="western"><surname>Beaussier</surname><given-names>H.</given-names></name><name name-style="western"><surname>Voisin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Jouveshomme</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dauriat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lazareth</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Anakinra for Severe Forms of COVID-19: A Cohort Study</article-title>. <source>Lancet Rheumatol.</source><volume>2</volume> (<issue>7</issue>), <fpage>e393</fpage>&#8211;<lpage>e400</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S2665-9913(20)30164-8</pub-id><pub-id pub-id-type="pmid">32835245</pub-id><pub-id pub-id-type="pmcid">PMC7259909</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iqubal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hoda</surname><given-names>F.</given-names></name><name name-style="western"><surname>Najmi</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>S. E.</given-names></name></person-group> (<year>2021</year>a). <article-title>Macrophage Activation and Cytokine Release Syndrome in COVID-19: Current Updates and Analysis of Repurposed and Investigational Anti-Cytokine Drugs</article-title>. <source>Drug Res.</source><volume>71</volume> (<issue>4</issue>), <fpage>173</fpage>&#8211;<lpage>179</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1055/a-1291-7692</pub-id><pub-id pub-id-type="pmid">33434935</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iqubal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iqubal</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>S. E.</given-names></name></person-group> (<year>2021</year>b). <article-title>Natural Products, a Potential Therapeutic Modality in Management and Treatment of Ncov-19 Infection: Preclinical and Clinical Based Evidence</article-title>. <source>Curr. Pharm. Des.</source><volume>27</volume> (<issue>9</issue>), <fpage>1153</fpage>&#8211;<lpage>1169</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.2174/1381612827999210111190855</pub-id><pub-id pub-id-type="pmid">33430746</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iqubal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iqubal</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Hoda</surname><given-names>F.</given-names></name><name name-style="western"><surname>Najmi</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>S. E.</given-names></name></person-group> (<year>2021</year>c). <article-title>COVID-19 and Cardiovascular Complications: An Update From the Underlying Mechanism to Consequences and Possible Clinical Intervention</article-title>. <source>Expert Rev. Anti Infect. Ther.</source><volume>19</volume>(<issue>9</issue>), <fpage>1083</fpage>&#8211;<lpage>1092</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14787210.2021.1893692</pub-id><pub-id pub-id-type="pmid">33618607</pub-id><pub-id pub-id-type="pmcid">PMC7938651</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isabel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gra&#241;a-Miraglia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Bundalovic-Torma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Groves</surname><given-names>H. E.</given-names></name><name name-style="western"><surname>Isabel</surname><given-names>M. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Evolutionary and Structural Analyses of SARS-CoV-2 D614G Spike Protein Mutation Now Documented Worldwide</article-title>. <source>Sci. Rep.</source><volume>10</volume> (<issue>1</issue>), <fpage>14031</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-020-70827-z</pub-id><pub-id pub-id-type="pmid">32820179</pub-id><pub-id pub-id-type="pmcid">PMC7441380</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>O. K.</given-names></name><name name-style="western"><surname>Al-Emran</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Anwar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jahid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>M. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Emergence of European and North American Mutant Variants of SARS-CoV-2 in South-East Asia</article-title>. <source>Transbound Emerg. Dis.</source><volume>68</volume> (<issue>2</issue>), <fpage>824</fpage>&#8211;<lpage>832</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/tbed.13748</pub-id><pub-id pub-id-type="pmid">32701194</pub-id><pub-id pub-id-type="pmcid">PMC7405211</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kamboj</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Plausible State-Specific Plans and Recommendations to Avert COVID-19 Community Transmission</article-title>. <source>Bull. Pure Appl. Sci. (Zool.)</source><volume>39A</volume> (<issue>2</issue>), <fpage>447</fpage>&#8211;<lpage>454</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.5958/2320-3188.2020.00051.0</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kali</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Dr&#246;ge</surname><given-names>P.</given-names></name><name name-style="western"><surname>Murugan</surname><given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>Interferon &#946;, an Enhancer of the Innate Immune Response Against SARS-CoV-2 Infection</article-title>. <source>Microb. Pathog.</source><volume>158</volume>, <elocation-id>105105</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.micpath.2021.105105</pub-id><pub-id pub-id-type="pmid">34311016</pub-id><pub-id pub-id-type="pmcid">PMC8302486</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalil</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>T. F.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Tomashek</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Ghazaryan</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Baricitinib Plus Remdesivir for Hospitalized Adults With Covid-19</article-title>. <source>N. Engl. J. Med.</source><volume>384</volume> (<issue>9</issue>), <fpage>795</fpage>&#8211;<lpage>807</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2031994</pub-id><pub-id pub-id-type="pmid">33306283</pub-id><pub-id pub-id-type="pmcid">PMC7745180</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Ransing</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arafat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>V.</given-names></name></person-group> (<year>2021</year>). <article-title>Second Wave of COVID-19 Pandemic in India: Barriers to Effective Governmental Response</article-title>. <source>EClinicalMedicine</source><volume>36</volume>, <elocation-id>100915</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.eclinm.2021.100915</pub-id><pub-id pub-id-type="pmid">34095794</pub-id><pub-id pub-id-type="pmcid">PMC8164526</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawabata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A Box-Shaped Shielding Device for Reducing the Risk of COVID-19 Droplet Infection During Gastrointestinal Endoscopic Procedures</article-title>. <source>J. Clin. Transl. Res.</source><volume>6</volume> (<issue>6</issue>), <fpage>236</fpage>&#8211;<lpage>240</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.18053/jctres.06.202006.00</pub-id><pub-id pub-id-type="pmid">33564728</pub-id><pub-id pub-id-type="pmcid">PMC7868116</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>P.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine</article-title>. <source>N. Engl. J. Med.</source><volume>383</volume> (<issue>24</issue>), <fpage>2320</fpage>&#8211;<lpage>2332</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korber</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Gnanakaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Theiler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abfalterer</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus</article-title>. <source>Cell</source><volume>182</volume> (<issue>4</issue>), <fpage>812</fpage>&#8211;<lpage>827.e19</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.06.043</pub-id><pub-id pub-id-type="pmid">32697968</pub-id><pub-id pub-id-type="pmcid">PMC7332439</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Vaccines in Development</article-title>. <source>Nature</source><volume>586</volume>, <fpage>516</fpage>&#8211;<lpage>527</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2798-3</pub-id><pub-id pub-id-type="pmid">32967006</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laurence</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mulvey</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Seshadri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Racanelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schenck</surname><given-names>E. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Anti-Complement C5 Therapy With Eculizumab in Three Cases of Critical COVID-19</article-title>. <source>Clin. Immunol. (Orlando Fla.)</source><volume>219</volume>, <elocation-id>108555</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.clim.2020.108555</pub-id><pub-id pub-id-type="pmcid">PMC7410014</pub-id><pub-id pub-id-type="pmid">32771488</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shum</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J. T.</given-names></name></person-group> (<year>2021</year>). <article-title>Early Transmissibility Assessment of the N501Y Mutant Strains of SARS-CoV-2 in the United Kingdom, October to November 2020</article-title>. <source>Euro Surveill.</source><volume>26</volume> (<issue>1</issue>), <elocation-id>2002106</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.26.1.2002106</pub-id><pub-id pub-id-type="pmcid">PMC7791602</pub-id><pub-id pub-id-type="pmid">33413740</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Structure, Function, and Evolution of Coronavirus Spike Proteins</article-title>. <source>Annu. Rev. Virol.</source><volume>3</volume> (<issue>1</issue>), <fpage>237</fpage>&#8211;<lpage>261</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev-virology-110615-042301</pub-id><pub-id pub-id-type="pmid">27578435</pub-id><pub-id pub-id-type="pmcid">PMC5457962</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Genomic Variation, Origin Tracing, and Vaccine Development of SARS-CoV-2: A Systematic Review</article-title>. <source>Innovation (N Y)</source><volume>2</volume> (<issue>2</issue>), <elocation-id>100116</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.xinn.2021.100116</pub-id><pub-id pub-id-type="pmid">33997827</pub-id><pub-id pub-id-type="pmcid">PMC8110321</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Vasilieva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Berne</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Angiotensin-Converting Enzyme 2 is a Functional Receptor for the SARS Coronavirus</article-title>. <source>Nature</source><volume>426</volume> (<issue>6965</issue>), <fpage>450</fpage>&#8211;<lpage>454</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id><pub-id pub-id-type="pmcid">PMC7095016</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipcsey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Persson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Blom</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Fromell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hultstr&#246;m</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The Outcome of Critically Ill COVID-19 Patients is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <elocation-id>627579</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.627579</pub-id><pub-id pub-id-type="pmid">33692801</pub-id><pub-id pub-id-type="pmcid">PMC7937878</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez Bernal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gower</surname><given-names>C.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stowe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tessier</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on Covid-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control Study</article-title>. <source>BMJ (Clinical Res. Ed.)</source><volume>373</volume>, <elocation-id>n1088</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1136/bmj.n1088</pub-id><pub-id pub-id-type="pmcid">PMC8116636</pub-id><pub-id pub-id-type="pmid">33985964</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez-Medina</surname><given-names>E.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hurtado</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>D&#225;valos</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial</article-title>. <source>JAMA</source><volume>325</volume> (<issue>14</issue>), <fpage>1426</fpage>&#8211;<lpage>1435</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.2021.3071</pub-id><pub-id pub-id-type="pmid">33662102</pub-id><pub-id pub-id-type="pmcid">PMC7934083</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahase</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>Covid-19: FDA Authorises Neutralising Antibody Bamlanivimab for Non-Admitted Patients</article-title>. <source>BMJ (Clinical Res. ed.)</source><volume>371</volume>:<elocation-id>m4362</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1136/bmj.m4362</pub-id><pub-id pub-id-type="pmid">33177042</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallah</surname><given-names>S. I.</given-names></name><name name-style="western"><surname>Ghorab</surname><given-names>O. K.</given-names></name><name name-style="western"><surname>Al-Salmi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abdellatif</surname><given-names>O. S.</given-names></name><name name-style="western"><surname>Tharmaratnam</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iskandar</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>COVID-19: Breaking Down a Global Health Crisis</article-title>. <source>Ann. Clin. Microbiol. Antimicrob.</source><volume>20</volume> (<issue>1</issue>), <fpage>35</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12941-021-00438-7</pub-id><pub-id pub-id-type="pmid">34006330</pub-id><pub-id pub-id-type="pmcid">PMC8129964</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rajpal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>V. K.</given-names></name></person-group> (<year>2021</year>). <article-title>Covid-19 Vaccines and New Mutant Strains Impacting the Pandemic</article-title>. <source>Indian J. Tuberc.</source><volume>68</volume> (<issue>2</issue>), <fpage>171</fpage>&#8211;<lpage>173</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ijtb.2021.03.010</pub-id><pub-id pub-id-type="pmid">33845947</pub-id><pub-id pub-id-type="pmcid">PMC8035083</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>An</surname><given-names>H.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Mansour</surname><given-names>O.</given-names></name><name name-style="western"><surname>Madhira</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rashidi</surname><given-names>E. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study</article-title>. <source>Ann. Intern. Med.</source><volume>174</volume>(<issue>10</issue>), <fpage>1395</fpage>&#8211;<lpage>1403</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.7326/M21-0857</pub-id><pub-id pub-id-type="pmid">34399060</pub-id><pub-id pub-id-type="pmcid">PMC8372837</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lydia</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Allam</surname><given-names>I.</given-names></name><name name-style="western"><surname>Djidjik</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Strat&#233;gies Vaccinales Contre Le SARS CoV-2</article-title>. <source>Rev. Algerienne Allergol.</source><volume>6</volume>, <fpage>8</fpage>&#8211;<lpage>22</lpage><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.asjp.cerist.dz/en/PresentationRevue/588">https://www.asjp.cerist.dz/en/PresentationRevue/588</uri>.</mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michot</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Albiges</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chaput</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saada</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pommeret</surname><given-names>F.</given-names></name><name name-style="western"><surname>Griscelli</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Tocilizumab, an Anti-IL-6 Receptor Antibody, to Treat COVID-19-Related Respiratory Failure: A Case Report</article-title>. <source>Ann. Oncol.</source><volume>31</volume> (<issue>7</issue>), <fpage>961</fpage>&#8211;<lpage>964</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.annonc.2020.03.300</pub-id><pub-id pub-id-type="pmid">32247642</pub-id><pub-id pub-id-type="pmcid">PMC7136869</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitj&#224;</surname><given-names>O.</given-names></name><name name-style="western"><surname>Corbacho-Monn&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ubals</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alemany</surname><given-names>A.</given-names></name><name name-style="western"><surname>Su&#241;er</surname><given-names>C.</given-names></name><name name-style="western"><surname>Teb&#233;</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19</article-title>. <source>N. Engl. J. Med.</source><volume>384</volume> (<issue>5</issue>), <fpage>417</fpage>&#8211;<lpage>427</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2021801</pub-id><pub-id pub-id-type="pmid">33289973</pub-id><pub-id pub-id-type="pmcid">PMC7722693</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Dowd</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Covid-19: Cases of Delta Variant Rise by 79%, But Rate of Growth Slows</article-title>. <source>BMJ</source><volume>373</volume>:<elocation-id>n1596</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1136/bmj.n1596</pub-id><pub-id pub-id-type="pmid">34154997</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oldenburg</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Doan</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>Azithromycin for Severe COVID-19</article-title>. <source>Lancet (London England)</source><volume>396</volume> (<issue>10256</issue>), <fpage>936</fpage>&#8211;<lpage>937</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31863-8</pub-id><pub-id pub-id-type="pmcid">PMC7833672</pub-id><pub-id pub-id-type="pmid">32896293</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omarjee</surname><given-names>L.</given-names></name><name name-style="western"><surname>Janin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perrot</surname><given-names>F.</given-names></name><name name-style="western"><surname>Laviolle</surname><given-names>B.</given-names></name><name name-style="western"><surname>Meilhac</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mahe</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Targeting T-Cell Senescence and Cytokine Storm With Rapamycin to Prevent Severe Progression in COVID-19</article-title>. <source>Clin. Immunol.</source><volume>216</volume>:<elocation-id>108464</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.clim.2020.108464</pub-id><pub-id pub-id-type="pmid">32405269</pub-id><pub-id pub-id-type="pmcid">PMC7217787</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oude Munnink</surname><given-names>B. B.</given-names></name><name name-style="western"><surname>Sikkema</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Nieuwenhuijse</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Molenaar</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Munger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Molenkamp</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Transmission of SARS-CoV-2 on Mink Farms Between Humans and Mink and Back to Humans</article-title>. <source>Science (New York N.Y.)</source><volume>371</volume> (<issue>6525</issue>), <fpage>172</fpage>&#8211;<lpage>177</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abe5901</pub-id><pub-id pub-id-type="pmcid">PMC7857398</pub-id><pub-id pub-id-type="pmid">33172935</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aondio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fumagalli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Efficacy and Tolerability of Bevacizumab in Patients With Severe Covid-19</article-title>. <source>Nat. Commun.</source><volume>12</volume> (<issue>1</issue>), <fpage>814</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-021-21085-8</pub-id><pub-id pub-id-type="pmid">33547300</pub-id><pub-id pub-id-type="pmcid">PMC7864918</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pater</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Bosmeny</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Barkay</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Ovington</surname><given-names>K. N.</given-names></name><name name-style="western"><surname>Chilamkurthy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parasrampuria</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Emergence and Evolution of a Prevalent New SARS-CoV-2 Variant in the United States</article-title>. <source>BioRxiv</source>. doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.01.11.426287</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Peshimam</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Farooq</surname><given-names>U.</given-names></name></person-group> (<year>2021</year>). <source>CanSinoBIO's COVID-19 Vaccine 65.7% Effective in Global Trials, Pakistan Official Says</source><publisher-loc>Islamabad</publisher-loc>: <publisher-name>Reuters</publisher-name>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.reuters.com/article/us-health-coronavirus-vaccine-pakistan-idUSKBN2A81N0">https://www.reuters.com/article/us-health-coronavirus-vaccine-pakistan-idUSKBN2A81N0</uri>.</mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piroth</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cottenet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mariet</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Bonniaud</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blot</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tubert-Bitter</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Comparison of the Characteristics, Morbidity, and Mortality of COVID-19 and Seasonal Influenza: A Nationwide, Population-Based Retrospective Cohort Study</article-title>. <source>Lancet Respir. Med.</source><volume>9</volume> (<issue>3</issue>), <fpage>251</fpage>&#8211;<lpage>259</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30527-0</pub-id><pub-id pub-id-type="pmid">33341155</pub-id><pub-id pub-id-type="pmcid">PMC7832247</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plante</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Lokugamage</surname><given-names>K. G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Spike Mutation D614G Alters SARS-CoV-2 Fitness</article-title>. <source>Nature</source><volume>592</volume> (<issue>7852</issue>), <fpage>116</fpage>&#8211;<lpage>121</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2895-3</pub-id><pub-id pub-id-type="pmid">33106671</pub-id><pub-id pub-id-type="pmcid">PMC8158177</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F. P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title>. <source>N. Engl. J. Med.</source><volume>383</volume> (<issue>27</issue>), <fpage>2603</fpage>&#8211;<lpage>2615</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Public Health England</collab></person-group> (<year>2021</year>). <source>SARS-CoV-2 Variants of Concern and Variants Under Investigation in England&#8212;technical Briefing 17</source> (<publisher-loc>London, United Kingdom</publisher-loc>: <publisher-name>Public Health England</publisher-name>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/997418/Variants_of_Concern_VOC_Technical_Briefing_17.pdfpdficonexternalicon">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/997418/Variants_of_Concern_VOC_Technical_Briefing_17.pdfpdficonexternalicon</uri>.</mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabaan</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Al-Ahmed</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Muhammad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sule</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Tirupathi</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm</article-title>. <source>Vaccines</source><volume>9</volume> (<issue>5</issue>):<elocation-id>436</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9050436</pub-id><pub-id pub-id-type="pmid">33946736</pub-id><pub-id pub-id-type="pmcid">PMC8145892</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qusairy</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Massip-Salcedo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Macip</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy</article-title><source>Mol. Cancer. Res.</source><volume>19</volume>, <issue>4</issue>, <fpage>549</fpage>&#8211;<lpage>554</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1158/1541-7786.MCR-20-0814</pub-id><pub-id pub-id-type="pmid">33328281</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Idid</surname><given-names>S. Z.</given-names></name></person-group> (<year>2021</year>). <article-title>Can Zn Be a Critical Element in COVID-19 Treatment</article-title>? <source>Biol. Trace Elem. Res.</source><volume>199</volume> (<issue>2</issue>), <fpage>550</fpage>&#8211;<lpage>558</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12011-020-02194-9</pub-id><pub-id pub-id-type="pmid">32458149</pub-id><pub-id pub-id-type="pmcid">PMC7250542</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Loman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pybus</surname><given-names>O.</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>W.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carabelli</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>) <source>Preliminary Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in the UK Defined by a Novel Set of Spike Mutations</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563">https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563</uri>.</mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezaei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Babamahmoodi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marjani</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19</article-title>. <source>Tanaffos</source><volume>19</volume> (<issue>2</issue>), <fpage>85</fpage>&#8211;<lpage>88</lpage><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/33262793/">https://pubmed.ncbi.nlm.nih.gov/33262793/</uri>.<pub-id pub-id-type="pmid">33262793</pub-id><pub-id pub-id-type="pmcid">PMC7680521</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oechsle</surname><given-names>O.</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Baricitinib as Potential Treatment for 2019-Ncov Acute Respiratory Disease</article-title>. <source>Lancet (London England)</source><volume>395</volume> (<issue>10223</issue>), <fpage>e30</fpage>&#8211;<lpage>e31</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30304-4</pub-id><pub-id pub-id-type="pmcid">PMC7137985</pub-id><pub-id pub-id-type="pmid">32032529</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lecl&#233;zio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sathianm</surname><given-names>B.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 and Mutations a Threat Level Assessment</article-title>. <source>Nepal J. Epidemiol.</source><volume>11</volume> (<issue>1</issue>), <fpage>983</fpage>&#8211;<lpage>987</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.3126/nje.v11i1.35659</pub-id><pub-id pub-id-type="pmid">33868743</pub-id><pub-id pub-id-type="pmcid">PMC8033641</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roschewski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lionakis</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Sharman</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Roswarski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monticelli</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Inhibition of Bruton Tyrosine Kinase in Patients With Severe COVID-19</article-title>. <source>Sci. Immunol.</source><volume>5</volume> (<issue>48</issue>), <fpage>eabd0110</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/sciimmunol.abd0110</pub-id><pub-id pub-id-type="pmid">32503877</pub-id><pub-id pub-id-type="pmcid">PMC7274761</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Roxby</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <source>Russian Covid Vaccine Shows Encouraging Results</source><publisher-loc>Moscow</publisher-loc>:(<publisher-name>BBC News</publisher-name>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bbc.com/news/health-54905330">https://www.bbc.com/news/health-54905330</uri>.</mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#350;im&#351;ek Yavuz</surname><given-names>S.</given-names></name><name name-style="western"><surname>&#220;nal</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Antiviral Treatment of COVID-19</article-title>. <source>Turk. J. Med. Sci.</source><volume>50</volume> (<issue>SI-1</issue>), <fpage>611</fpage>&#8211;<lpage>619</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.3906/sag-2004-145</pub-id><pub-id pub-id-type="pmid">32293834</pub-id><pub-id pub-id-type="pmcid">PMC7195979</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saber-Ayad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hammoudeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abu-Gharbieh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hamoudi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tarazi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Al-Tel</surname><given-names>T. H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Current Status of Baricitinib as a Repurposed Therapy for COVID-19</article-title>. <source>Pharmaceuticals (Basel Switzerland)</source><volume>14</volume> (<issue>7</issue>):<elocation-id>680</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ph14070680</pub-id><pub-id pub-id-type="pmcid">PMC8308612</pub-id><pub-id pub-id-type="pmid">34358107</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabino</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Buss</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prete</surname><given-names>C. A.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Crispim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fraiji</surname><given-names>N. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Resurgence of COVID-19 in Manaus, Brazil, Despite High Seroprevalence</article-title>. <source>Lancet (London England)</source><volume>397</volume> (<issue>10273</issue>), <fpage>452</fpage>&#8211;<lpage>455</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(21)00183-5</pub-id><pub-id pub-id-type="pmcid">PMC7906746</pub-id><pub-id pub-id-type="pmid">33515491</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Le Gars</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G.</given-names></name><name name-style="western"><surname>Heerwegh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Truyers</surname><given-names>C.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>A. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine</article-title>. <source>N. Engl. J. Med.</source><volume>384</volume> (<issue>19</issue>), <fpage>1824</fpage>&#8211;<lpage>1835</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2034201</pub-id><pub-id pub-id-type="pmid">33440088</pub-id><pub-id pub-id-type="pmcid">PMC7821985</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvatore</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bhattacharyya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Purkayastha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hazra</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Resurgence of SARS-CoV-2 in India: Potential Role of the B.1.617.2 (Delta) Variant and Delayed Interventions</article-title>. <source>MedRxiv</source>. doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.06.23.21259405</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>b). <article-title>Comprehensive Analysis of Genomic Diversity of SARS-CoV-2 in Different Geographic Regions of India: An Endeavour to Classify Indian SARS-CoV-2 Strains on the Basis of Co-Existing Mutations</article-title>. <source>Arch. Virol.</source><volume>166</volume> (<issue>3</issue>), <fpage>801</fpage>&#8211;<lpage>812</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00705-020-04911-0</pub-id><pub-id pub-id-type="pmid">33464421</pub-id><pub-id pub-id-type="pmcid">PMC7814186</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mallick</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>a). <article-title>Emergence of a New SARS-CoV-2 Variant From GR Clade With a Novel S Glycoprotein Mutation V1230L in West Bengal, India</article-title>. <source>MedRxiv</source>. doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.05.24.21257705</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>On the Use of Corticosteroids for 2019-nCoV Pneumonia</article-title>. <source>Lancet (London England)</source><volume>395</volume> (<issue>10225</issue>), <fpage>683</fpage>&#8211;<lpage>684</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30361-5</pub-id><pub-id pub-id-type="pmcid">PMC7159292</pub-id><pub-id pub-id-type="pmid">32122468</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrotri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krutikov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Giddings</surname><given-names>R.</given-names></name><name name-style="western"><surname>Azmi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Vaccine Effectiveness of the First Dose of ChAdOx1 Ncov-19 and BNT162b2 Against SARS-CoV-2 Infection in Residents of Long-Term Care Facilities (VIVALDI Study)</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>(<issue>11</issue>), <fpage>1529</fpage>&#8211;<lpage>1538</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1101/2021</pub-id><pub-id pub-id-type="pmid">34174193</pub-id><pub-id pub-id-type="pmcid">PMC8221738</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Sak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tuli</surname><given-names>H. S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19 Pandemic: From Molecular Biology, Pathogenesis, Detection, and Treatment to Global Societal Impact</article-title>. <source>Curr. Pharmacol. Rep.</source><volume>1</volume>, <fpage>16</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s40495-020-00229-2</pub-id><pub-id pub-id-type="pmcid">PMC7382994</pub-id><pub-id pub-id-type="pmid">32837855</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stasi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fallani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Voller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Treatment for COVID-19: An Overview</article-title>. <source>Eur. J. Pharmacol.</source><volume>889</volume>, <elocation-id>173644</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173644</pub-id><pub-id pub-id-type="pmid">33053381</pub-id><pub-id pub-id-type="pmcid">PMC7548059</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stebbing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oechsle</surname><given-names>O.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19: Combining Antiviral and Anti-Inflammatory Treatments</article-title>. <source>Lancet Infect. Dis.</source><volume>20</volume> (<issue>4</issue>), <fpage>400</fpage>&#8211;<lpage>402</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30132-8</pub-id><pub-id pub-id-type="pmid">32113509</pub-id><pub-id pub-id-type="pmcid">PMC7158903</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez Bernal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gower</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thelwall</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Effectiveness of COVID-19 Vaccines Against Hospital Admission With the Delta (B.1.617.2) Variant</article-title><source>N Engl, J Med</source><volume>385</volume>(<issue>7</issue>):<page-range>585&#8211;94</page-range> . doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2108891</pub-id><pub-id pub-id-type="pmcid">PMC8314739</pub-id><pub-id pub-id-type="pmid">34289274</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supasa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dejnirattisai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Ginn</surname><given-names>H. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant by Convalescent and Vaccine Sera</article-title>. <source>Cell</source><volume>184</volume> (<issue>8</issue>), <fpage>2201</fpage>&#8211;<lpage>2211:e7</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2021.02.033</pub-id><pub-id pub-id-type="pmid">33743891</pub-id><pub-id pub-id-type="pmcid">PMC7891044</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>On the Origin and Continuing Evolution of SARS-CoV-2</article-title>. <source>Natl. Sci. Rev.</source><volume>7</volume> (<issue>6</issue>), <fpage>1012</fpage>&#8211;<lpage>1023</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nsr/nwaa036</pub-id><pub-id pub-id-type="pmid">34676127</pub-id><pub-id pub-id-type="pmcid">PMC7107875</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tardif</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Bouabdallaoui</surname><given-names>N.</given-names></name><name name-style="western"><surname>L&#8217;Allier</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Gaudet</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pillinger</surname><given-names>M. H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Efficacy of Colchicine in non-Hospitalized Patients With COVID-19</article-title>. <source>Medrxiv</source>. doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.01.26.21250494v1</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tegally</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lessells</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Giandhari</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pillay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Msomi</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Sixteen Novel Lineages of SARS-CoV-2 in South Africa</article-title>. <source>Nat. Med.</source><volume>27</volume> (<issue>3</issue>), <fpage>440</fpage>&#8211;<lpage>446</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41591-021-01255-3</pub-id><pub-id pub-id-type="pmid">33531709</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Tomkins-Tinch</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Silbert</surname><given-names>J.</given-names></name><name name-style="western"><surname>DeRuff</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Siddle</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Gladden-Young</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bronson</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>) <source>Detection of the Recurrent Substitution Q677H in the Spike Protein of SARS-CoV-2 in Cases Descended From the Lineage B.1.429</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://virological.org/c/novel-2019-coronavirus/ncov-2019-genomic-epidemiology/36">https://virological.org/c/novel-2019-coronavirus/ncov-2019-genomic-epidemiology/36</uri>.</mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tortajada</surname><given-names>C.</given-names></name><name name-style="western"><surname>A&#241;&#243;n</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Andreu-Ballester</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Flores</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Interferon &#946;-1b for Patients With Moderate to Severe COVID-19 in the Inflammatory Phase of the Disease</article-title>. <source>J. Med. Virol.</source><volume>93</volume> (<issue>7</issue>), <fpage>4102</fpage>&#8211;<lpage>4107</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jmv.26976</pub-id><pub-id pub-id-type="pmid">33856708</pub-id><pub-id pub-id-type="pmcid">PMC8251165</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuli</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Sood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Punia</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Mechanistic Insight Into Anti-COVID-19 Drugs: Recent Trends and Advancements</article-title>. <source>3 Biotech</source><volume>11</volume>, <fpage>110</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s13205-021-02644-8</pub-id><pub-id pub-id-type="pmcid">PMC7851641</pub-id><pub-id pub-id-type="pmid">33552835</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upadhyay</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Girdhar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rastogi</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Recent Advancement in SARS-CoV-2 Diagnosis, Treatment, and Vaccine Formulation: A New Paradigm of Nanotechnology in Strategic Combating of COVID-19 Pandemic</article-title>. <source>Curr. Pharmacol. Rep.</source>, <fpage>1</fpage>&#8211;<lpage>14</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s40495-021-00250-z</pub-id><pub-id pub-id-type="pmcid">PMC7854874</pub-id><pub-id pub-id-type="pmid">33552875</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upadhyay</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Babita</surname></name><name name-style="western"><surname>Kumar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>b). <article-title>The Outbreak and Challenges of Novel Coronavirus (COVID-19): The Global Pandemic Emergency of Early 2K20 and Indian Scenario</article-title>. <source>Int. J. Biol. Pharm. Allied Sci.</source><volume>9</volume> (<issue>5</issue>), <fpage>1173</fpage>&#8211;<lpage>1199</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.31032/IJBPAS/2020/9.5.5126</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upadhyay</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>a). <article-title>COVID-19 in Republic of India: A Report on Situation and Precautionary Strategies to Global Pandemic</article-title>. <source>Bull. Environ. Pharmacol. Life Sci.</source><volume>9</volume> (<issue>6</issue>), <fpage>39</fpage>&#8211;<lpage>48</lpage><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bepls.com/bepls_may2020/7.pdf">http://bepls.com/bepls_may2020/7.pdf</uri>.</mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urwyler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>S.</given-names></name><name name-style="western"><surname>Charitos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Heijnen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rudin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sommer</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System</article-title>. <source>Front. Immunol.</source><volume>11</volume>:<elocation-id>2072</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2020.02072</pub-id><pub-id pub-id-type="pmid">32922409</pub-id><pub-id pub-id-type="pmcid">PMC7456998</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verderese</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Stepanova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>B.</given-names></name><name name-style="western"><surname>Racila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolacevski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience</article-title>. <source>Clin. Infect. Dis.</source><fpage>ciab579</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/cid/ciab579</pub-id><pub-id pub-id-type="pmid">34166513</pub-id><pub-id pub-id-type="pmcid">PMC8344419</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vetter</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>L.</given-names></name><name name-style="western"><surname>Calmy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agoritsas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Huttnerm</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Dexamethasone and Remdesivir: Finding Method in the COVID-19 Madness</article-title>. <source>Lancet Microbe</source><volume>1</volume> (<issue>8</issue>), <fpage>e309</fpage>&#8211;<lpage>e310</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2666-5247(20)30173-7</pub-id><pub-id pub-id-type="pmid">35544181</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>V.</given-names></name><name name-style="western"><surname>McCrone</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Price</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jorgensen</surname><given-names>D.</given-names></name><name name-style="western"><surname>O'Toole</surname><given-names>&#193;.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity</article-title>. <source>Cell</source><volume>184</volume> (<issue>1</issue>), <fpage>64</fpage>&#8211;<lpage>75.e11</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.11.020</pub-id><pub-id pub-id-type="pmid">33275900</pub-id><pub-id pub-id-type="pmcid">PMC7674007</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>S.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>L. Y.</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P. K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety and Efficacy of the ChAdOx1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK</article-title>. <source>Lancet (London England)</source><volume>397</volume> (<issue>10269</issue>), <fpage>99</fpage>&#8211;<lpage>111</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id><pub-id pub-id-type="pmid">33306989</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vudathaneni</surname><given-names>V. K. P.</given-names></name><name name-style="western"><surname>Nadella</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Lanke</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Boyapati</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Coronavirus Disease and Cardiovascular Disease: A Literature Review</article-title>. <source>J. Clin. Transl. Res.</source><volume>7</volume> (<issue>2</issue>), <fpage>156</fpage>&#8211;<lpage>162</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.18053/jctres.07.202102.00</pub-id><pub-id pub-id-type="pmid">34104818</pub-id><pub-id pub-id-type="pmcid">PMC8177845</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Receptor Recognition by the Novel Coronavirus From Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus</article-title>. <source>J. Virol.</source><volume>94</volume> (<issue>7</issue>), <fpage>e00127</fpage>&#8211;<lpage>e00120</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/JVI.00127-20</pub-id><pub-id pub-id-type="pmid">31996437</pub-id><pub-id pub-id-type="pmcid">PMC7081895</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinreich</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Sivapalasingam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bhore</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients With Covid-19</article-title>. <source>N. Engl. J. Med.</source><volume>384</volume> (<issue>3</issue>), <fpage>238</fpage>&#8211;<lpage>251</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2035002</pub-id><pub-id pub-id-type="pmid">33332778</pub-id><pub-id pub-id-type="pmcid">PMC7781102</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>C. O.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bjorkman</surname><given-names>P. J.</given-names></name></person-group> (<year>2021</year>a). <article-title>SARS-CoV-2 Lineage B.1.526 Emerging in the New York Region Detected by Software Utility Created to Query the Spike Mutational Landscape</article-title>. <source>BioRxiv</source>. doi:&#160;<pub-id pub-id-type="doi">10.1101/2021.02.14.431043</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>A. P.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Wertheim</surname><given-names>J. O.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Vasylyeva</surname><given-names>T. I.</given-names></name><name name-style="western"><surname>Havens</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2021</year>b). <article-title>Detection and Characterization of the SARS-CoV-2 Lineage B.1.526 in New York</article-title>. <source>Nat. Commun.</source><volume>12</volume> (<issue>1</issue>), <fpage>4886</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-021-25168-4</pub-id><pub-id pub-id-type="pmid">34373458</pub-id><pub-id pub-id-type="pmcid">PMC8352861</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2021</year>a) <source>Tracking SARS-CoV-2 Variants</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/activities/tracking-SARS-CoV-2-variants">https://www.who.int/activities/tracking-SARS-CoV-2-variants</uri>.</mixed-citation></ref><ref id="B127"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2021</year>b) <source>Weekly Epidemiological Update on COVID-19</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19&#x2014;11-may-2021">https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19&#8212;11- may-2021</uri>.</mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Vusirikala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ladhani</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>R. O. E.</given-names></name><name name-style="western"><surname>Iyanger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aiano</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>An Outbreak Caused by the SARS-CoV-2 Delta (B.1.617.2) Variant in a Care Home After Partial Vaccination With a Single Dose of the COVID-19 Vaccine Vaxzevria, London, England, April 2021</article-title>. <source>Euro Surveill.</source><volume>26</volume> (<issue>27</issue>), <elocation-id>2100626</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.2807/1560-7917.ES.2021.26.27.2100626</pub-id><pub-id pub-id-type="pmcid">PMC8268653</pub-id><pub-id pub-id-type="pmid">34240699</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dhiman</surname><given-names>U.</given-names></name><name name-style="western"><surname>Parihar</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>S. K.</given-names></name></person-group> (<year>2021</year>a). <article-title>Virtual Screening of Potential Drug Molecules Against Covid-19 Targets: A Drug Repurposing Approach</article-title>. <source>Lett. Appl. NanoBioScience</source><volume>11</volume> (<issue>1</issue>), <fpage>2965</fpage>&#8211;<lpage>2980</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.33263/LIANBS111.29652980</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parihar</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Dhiman</surname><given-names>U.</given-names></name><name name-style="western"><surname>Dhamija</surname><given-names>P.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Imran</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>b). <article-title>Docking of FDA Approved Drugs Targeting NSP-16, N-Protein and Main Protease of SARS-CoV-2 as Dual Inhibitors</article-title>. <source>Biointerface Res. Appl. Chem.</source><volume>11</volume> (<issue>3</issue>), <fpage>9848</fpage>&#8211;<lpage>9861</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.33263/BRIAC113.98489861</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>You</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The COVID-19 Vaccines: Recent Development, Challenges and Prospects</article-title>. <source>Vaccines</source><volume>9</volume> (<issue>4</issue>), <elocation-id>349</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9040349</pub-id><pub-id pub-id-type="pmid">33916489</pub-id><pub-id pub-id-type="pmcid">PMC8067284</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Leo</surname><given-names>Y. S.</given-names></name></person-group> (<year>2021</year>). <article-title>The Place for Remdesivir in COVID-19 Treatment</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume> (<issue>1</issue>), <fpage>20</fpage>&#8211;<lpage>21</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30911-7</pub-id><pub-id pub-id-type="pmid">33248473</pub-id><pub-id pub-id-type="pmcid">PMC7837362</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuen</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Nsp13, Nsp14, Nsp15 and Orf6 Function as Potent Interferon Antagonists</article-title>. <source>Emerg. Microbes Infect.</source><volume>9</volume> (<issue>1</issue>), <fpage>1418</fpage>&#8211;<lpage>1428</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/22221751.2020.1780953</pub-id><pub-id pub-id-type="pmid">32529952</pub-id><pub-id pub-id-type="pmcid">PMC7473193</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>B. D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Sincuir Martinez</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Plummer</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Vail</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>Emergence of a Novel SARS-CoV-2 Variant in Southern California</article-title>. <source>JAMA</source><volume>325</volume> (<issue>13</issue>), <fpage>1324</fpage>&#8211;<lpage>1326</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.2021.1612</pub-id><pub-id pub-id-type="pmid">33571356</pub-id><pub-id pub-id-type="pmcid">PMC7879386</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dejnirattisai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Supasa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Ginn</surname><given-names>H. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Evidence of Escape of SARS-CoV-2 Variant B.1.351 From Natural and Vaccine-Induced Sera</article-title>. <source>Cell</source><volume>184</volume> (<issue>9</issue>), <fpage>2348</fpage>&#8211;<lpage>2361.e6</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2021.02.037</pub-id><pub-id pub-id-type="pmid">33730597</pub-id><pub-id pub-id-type="pmcid">PMC7901269</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group> (<year>2021</year>). <article-title>Fast-Spreading SARS-CoV-2 Variants: Challenges to and New Design Strategies of COVID-19 Vaccines</article-title>. <source>Signal Transduct. Target. Ther.</source><volume>6</volume>, <fpage>226</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41392-021-00644-x</pub-id><pub-id pub-id-type="pmid">34108440</pub-id><pub-id pub-id-type="pmcid">PMC8187888</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X. G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>l.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin</article-title>. <source>Nature</source><volume>579</volume>, <fpage>270</fpage>&#8211;<lpage>273</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>